




# 2<sup>nd</sup> ANNUAL REPORT 2013-14



**Biotechnology Industry Research Assistance Council**  
(A Govt. of India Enterprise)



# 2<sup>nd</sup> ANNUAL REPORT 2013-14



**Biotechnology Industry Research Assistance Council**  
(A Govt. of India Enterprise)

# About BIRAC

## Focus

Empowering and Enabling the Biotech Innovation Ecosystem for affordable product development

## Vision

“Stimulate, foster and enhance the strategic research and innovation capabilities of the Indian biotech industry, particularly start-ups and SME's, for creation of affordable products addressing the needs of the largest section of society.”

## Key Strategies

- Foster innovation and entrepreneurship in all places of research
- Promote affordable innovation in key social sectors
- Higher focus on start-ups & small and medium enterprises
- Contribute through partners for capability enhancement
- Encourage diffusion of innovation through partners
- Enable commercialization of discovery
- Ensure global competitiveness of Indian enterprises

## BIRAC's Core Values

- Integrity
- Transparency
- Team work
- Excellence
- Commitment



BIRAC is a Section 25, "Not-for-profit Company" (now a Section 8 Company under the Companies Act, 2013) set up by Department of Biotechnology, Government of India as its interface agency to serve emerging biotech industries. A Schedule 'B' Public Sector Undertaking, BIRAC is guided by an independent Board of Directors comprising of senior professionals, academicians, policy makers and industrialists. To serve various dimensions of its mandate, BIRAC operates mainly in 3 verticals. Investment schemes provide funding support to entrepreneurs, start-ups, SMEs and Biotech Companies for all stages of the product development value chain from discovery to proof of concept to early and late stage development to validation and scale up, right upto pre-commercialization. There are also special product development missions. The second vertical is Entrepreneurship Development which focusses not only on the funding support, but also on making available the right infrastructure, mentoring and other networks for technology transfer and licensing, IP and business mentoring including regulatory guidance. Lastly BIRAC's strategic partnership group works closely with all partners – national and international which includes Government departments and ministries both Central and State, industry organisations, international bilateral agencies, philanthropic organisations and corporate sector, to leverage the strength and expertise and mobilize resources and extend the outreach of its activities.

Some of the key components are:-

### Investment for Affordable Products

**BIG:** Biotechnology Ignition Grant (BIG) is available to scientist entrepreneurs from research institutes, academia and start-ups. It is designed to stimulate commercialisation of research discoveries by providing very early stage grants to help bridge the gap between discovery and invention. The BIG innovators receive mentoring and networking help from five BIG partners (C-CAMP Bangalore, IKP Hyderabad, FITT, IIT Delhi, NCL Venture Center Pune and KIIT-TBI Bhubaneshwar).

**SBIRI:** Small Business Innovation Research Initiative (SBIRI) is the first of its kind PPP initiative to support early stage innovation focussed incremental R&D in the area of Biotechnology to facilitate risk taking ability by SMEs.

**BIPP:** Biotechnology Industry Partnership Programme (BIPP) seeks to provide support for high risk discovery to early to late stage innovation research in biotech industry and/or accelerate commercialisation of new indigenous technologies. It is a partnership scheme which is on a 50:50 cost sharing model.

**CRSS:** Contract Research and Services Scheme (CRSS) supports academic institutes across the country to take forward their research leads through a validation and translation by the industry. Funding is in the form of grant given to both the academic as well as the industrial partner. While the industry performs its

role as a validation partner and engages on a contractual basis, the IP rights reside solely with the academic partner.

**SPARSH:** Social Innovation Programme for Products Affordable and Relevant to Societal Health combines social innovation and biotechnology for the well-being of the society by helping identify and support cutting edge innovations towards affordable product development with potentially significant social impact. SPARSH provides support in the form of impact funding and fellowships for discovery, to POC to late stage validation.





### **Incubation**

**BISS:** Bioincubator Support Scheme strengthens and upgrades the existing bioincubators and establishes new world class bioincubators in certain strategic locations to encourage techno entrepreneurship. These bioincubators provide incubation space and other required services to young entrepreneurs and start-up companies for their initial growth.

**UIC:** The University Innovation Cluster (UIC) initiative focuses on students and young researchers of universities and research institutes. These were established in universities having an innovation research culture, good mentors and connections with industry. They are operated through cluster innovation centres for biotechnology which play the role of facilitators to stimulate entrepreneurial activities within the universities/ academic institutions and linkages with the industry. It provides innovation fellowship and research grants for its fellows.

### **International Partnerships**

**DBT-BMGF:** BIRAC operates the Project Management Unit of the DBT-Bill and Melinda Gates Foundation collaboration to support collaborative scientific and technological research to alleviate some of the world's most critical global health and development issues. Two Grand Challenges initiatives have been supported.

**Wellcome Trust:** The BIRAC-Wellcome Trust Joint Call in Translational Medicine aims to fund translational research projects to deliver safe and effective healthcare products for India at affordable costs, under the current theme of "Diagnostics for infectious diseases"

**Indo - CEFIPRA:** BIRAC has signed an Agreement with the French Embassy, India and Indo French Centre, New Delhi, to operate a joint research and development call for innovation research involving academia and industry, from both India and France.

# Contents

1.	Notice	1
2.	Chairman's Message	2
3.	Managing Director's Message	3
4.	Board of Directors	4-6
5.	Corporate Information	7
6.	Directors' Report	10-12
7.	Management Discussion & Analysis	14-36
8.	Secretarial Audit Report	37-40
9.	Corporate Governance Report	42-45
10.	CG Certificate on Corporate Governance	46
11.	Auditors Report	48-49
12.	Balance Sheet	50
13.	Income & Expenditure Statement	51
14.	Schedules	52-65
15.	Comments of Controller and Auditor General Account (C & AG)	66
16.	Proxy & Attendance Sheet	69







**Biotechnology Industry Research Assistance Council**

CIN: U73100DL2012NPL233152

Regd. office: 1<sup>st</sup> Floor, MTNL Building, 9, CGO Complex, Lodhi Road, New Delhi-110003

Website: www.birac.nic.in, Email: birac.dbt@nic.in, Tel: +91-11-24389600

## NOTICE

Notice is hereby given that the 2<sup>nd</sup> Annual General Meeting of the Company will be held on

**Day & Date : Tuesday, 30<sup>th</sup> September 2014**

**Time : 10.00 a.m.**

**Venue : 1<sup>st</sup> Floor, MTNL Building, 9, CGO Complex, Lodhi Road, New Delhi-110003**  
for transacting the following Business:

### Ordinary Business:

1. To receive, consider and adopt the Audited Financial Statement of the Company as on March 31, 2014 together with the Reports of the Directors and Auditors thereon and comments of the Comptroller & Auditor General of India in terms of Section 143(6) & (7) of the Companies Act, 2013
2. To authorise the Board of Directors of the Company to fix the remuneration of the Statutory Auditor for the financial year 2014-15 ,in terms of provisions of Section 139(5) read with Section 142 of the Companies Act, 2013 and to pass with or without modification(s) the following resolution as an Ordinary Resolution:  
**"RESOLVED THAT** the Board of Directors of the Company be and are hereby authorised to decide and fix the remuneration of the Statutory Auditor of the Company for the Financial Year 2014-15 as may be deemed fit by the Board."

### Notes To Notice Of The Meeting:

1. MEMBERS ENTITLED TO ATTEND AND VOTE MAY APPOINT ONE OR MORE PROXIES TO ATTEND AND VOTE INSTEAD OF THEMSELVES. PROXIES TO BE VALID MUST BE RECEIVED AT THE REGISTERED OFFICE OF THE COMPANY NOT LESS THAN FORTY-EIGHT HOURS BEFORE THE APPOINTED TIME OF THE MEETING
2. Only bonafide members of the Company whose names appear in the Register of Members in possession of valid attendance slips duly filed and signed will be permitted to attend the meeting. The Company reserves its right to take all steps as may be deemed necessary to restrict non-members from attending the meeting.
3. All documents referred in the notice are open for inspection at the Registered Office of the Company between 10.00 a.m. to 1.00 p.m. on any working day up to the date of Annual General Meeting and also at the meeting.
4. It will be appreciated that queries, if any, on accounts and operations of the Company are sent to the Registered office of the Company ten days in advance of the meeting so that the information may be made readily available.
5. Members are requested to notify change of address, if any, to the company.

### Registered Office:

1<sup>st</sup> Floor, MTNL Building, 9, CGO Complex,  
Lodhi Road, New Delhi-110003

By Order of the Board  
**Kavita Anandani**  
Company Secretary

**Date: 9<sup>th</sup> September, 2014**

**Place : New Delhi**



## Chairman's Message

It gives me great pleasure to present before you the Second Annual Report of BIRAC.

India is going through an extraordinary phase in its history, akin only to the challenges it faced at independence. Today, as in 1947, there is a renewed attempt to use knowledge and science as a component of social and economic change. In one perspective, India is full of problems. Health, agriculture, nutrition, sanitation, energy, infrastructure, manufacturing, the eco-system, are all major areas that need to be urgently addressed. In another perspective, India's continued investment over the past six decades in science and technology has been paying off in ways which position it to address the post complex of challenges. In this context, the key question that BIRAC faces is as simple as the answer is complex: How can BIRAC, with its modest resources, catalyse the biotech industry and entrepreneurial space into being socially and economically transformative? The answer to this question is what we grapple with at BIRAC constantly.

The foundations of our ventures lie in understanding and using the best in science and technology. From these foundations we reach out in every way to scientists, entrepreneurs, industry and science agencies in India and the world over. BIRAC's structure and its purpose to connect knowledge for public-good make its position and mandate unique. Just two years old, we have a lot to learn, but we have a preternatural ability to deal with complex problems. This has come about only because of the early nurturing by our partners. These are the Department of Biotechnology, various ministries in the Government of India and our extraordinary national and international collaborators.

Because of our accelerated growth, BIRAC has taken on many tasks in catalysing innovation in several biotechnology sectors. The canvas of urgent problems in India is huge. On one hand, BIRAC will find it difficult to neglect any part of this canvas and on the other it does not currently have the wherewithal to deal with all of it. As we meet in our second year, we hope to solve such conundrums through partnerships. The shared commitment that we share with all our partners is what makes us confident that we will paint the broad canvas well for India and the planet's future.

I would like to use this opportunity to reiterate BIRAC's commitment to do everything to work together with our community and our partners in the coming years and to congratulate all of BIRAC's staff in their extraordinary zeal and motivation.

It is noteworthy to mention that BIRAC has occupied a space which was not occupied earlier and the performance is impressive. The first MOU performance was rated "Excellent" receiving a score of 94% for CPSE grading on basis of Compliance with Guidelines on Corporate Governance for Central Public Sector Enterprises (CPSE) for the financial year 2012-13 by the Department of Public Enterprises. In a short span of two years the Company has taken swift steps to fulfil its Corporate Governance parameters and induct an independent Board of Eminent Scientists and is preparing to scale up its operations in the next three years.

Date: 9<sup>th</sup> September, 2014  
Place: New Delhi

**Prof. K. VijayRaghavan**  
Chairman, BIRAC



## Managing Director's Message

It is a matter of great delight that BIRAC completed two years of its successful existence on 20<sup>th</sup> March 2014. During the year, a landmark in BIRAC's journey was its categorization as a Schedule 'B' Public Sector Undertaking. From day one, BIRAC's thrust has been on creating an Innovation ecosystem that is conducive to the needs of young entrepreneurs and start-ups and networking them in such a manner that their ideas and discoveries stand up to their full potential through the rigors of the product development pipeline. In the institutional space, BIRAC strives to leverage national and international expertise through strategic partnerships to help Indian biotech enterprises to become globally competitive.

Given the urgency of requirements of SMEs in the biotech sector, BIRAC launched unique models of innovation funding and ecosystem development. In a short span of time BIRAC has notched up impressive results. It has reached out to more than 250 companies, mainly start-ups and SMEs, and has also supported more than 100 young entrepreneurs through seed funding. Additionally, BIRAC has provided incubation space and mentoring for IP & technology management and business development to more than 100 companies.

It is now well recognized that S&T agencies of the country need to establish a sustained dialogue not only with their direct stakeholders but also with the society at large, to create a constituency of support for S&T and to draw in fresh talent to take pursuit of science forward.

BIRAC has during the year worked very closely with all Stakeholders – both national and international. Close interaction with central and state Governments, ministries and Departments has resulted in taking the benefits of the domain specialisation to other sectors and regions. International partnerships such as with the Bill and Melinda Gates Foundation, Wellcome Trust, USAID, CEFIPRA and French Embassy have encouraged bilateral partnerships for academia industry innovation research for product development. BIRAC looks forward to reaching out to a larger number of target beneficiaries and stakeholders.

**Dr Renu Swarup**  
Managing Director, BIRAC

## BOARD OF DIRECTORS

<b>Prof. K. VijayRaghavan</b>	<b>:</b>	<b>Chairman</b>	<b>Non-Executive Independent Directors</b>
<b>Dr. Renu Swarup</b>	<b>:</b>	<b>Managing Director</b>	<b>Prof. Ashok Jhunjunwala : Director</b>
			<b>Dr. Gagandeep Kang : Director</b>
			<b>Prof. Deepak Pental : Director</b>
			<b>Dr. Dinakar M Salunke : Director</b>
			<b>Dr. Mohd.Aslam : Director</b>
			<b>(Government Nominee)</b>

### Profile of Prof. K. VijayRaghavan



Professor K. VijayRaghavan is the Secretary, Department of Biotechnology, Government of India since January 28, 2013. Before that, he was the Director of the National Centre for Biological Sciences (NCBS) of the Tata Institute of Fundamental Research (TIFR) and the interim head of The Institute of Stem Cell Biology and Regenerative Medicine (inStem) a new autonomous institute of the Department of Biotechnology (DBT). Prof. VijayRaghavan's contributions in science, as a developmental biologist, have been recognized widely. He was conferred an honorary Doctor of Science degree by the University of Edinburgh in 2011. He is a J. C. Bose Fellow of the Department of Science and Technology. He gave the J.C. Bose Memorial Lecture at the Royal Society in 2010, was awarded the inaugural Infosys Prize in Life Sciences 2009. He is a recipient of Shanti Swarup Bhatnagar Prize, India's most prestigious science award, in 1998. He is a fellow of The Indian National Science Academy

and The Indian Academy of Sciences and served on the Council of the latter. Prof. VijayRaghavan is the only Indian elected as an Associate Member of the European Molecular Biology Organization. In 2012, Prof. VijayRaghavan was elected a Fellow of the Royal Society.

### Profile of Dr. Renu Swarup

Dr. Renu Swarup is presently Senior Adviser to the Department of Biotechnology (DBT). A PhD in Genetics and Plant Breeding, Dr. Renu Swarup completed her Post-Doctoral at The John Innes Centre, Norwich UK, under Commonwealth Scholarship and returned to India to take up the assignment of a Science Manager in the Department of Biotechnology, Ministry of Science and Technology, Govt, in 1989. At DBT, she heads the National Bioresource Development Board and is involved in developing, funding and monitoring programmes in the area of Energy Biosciences, Bioresource Development and Utilization and Plant Biotechnology - Bio prospecting, Tissue Culture and other Biomass associated programmes. As a Science Manager, issues related to policy planning and implementation are also a part of her assignment.



She was actively engaged in formulation of the Biotechnology Vision in 2001 and National Biotechnology Development Strategy in 2007 as the Member Secretary of the Expert Committee. She was also a member of the Task Force on Women in Science constituted by the Scientific Advisory Committee to the Prime Minister. She was awarded the "Bio Spectrum Person of the Year Award" in 2012.

## Profile of Independent Directors

### Prof. Ashok Jhunjunwala

Prof. Jhunjunwala is an Institute Professor at IIT Madras. He received his B.Tech degree from IIT, Kanpur, and his MS and Ph.D degrees from the University of Maine. From 1979 to 1981, he was with the Washington State University and has been at IIT Madras ever-since, where he leads the Telecommunications and Computer Networks group (TeNeT). The group works with industry in the development of telecom, banking, IT and Power Systems (including solar) technologies relevant to India and has a special focus on rural technologies. It has incubated more than seventy companies in the last twenty years. He chairs IITM Incubation cell, Health Technology Innovation Center (HTIC), co-chairs Rural Technology and Business Incubator (RTBI) at IIT Madras



and is professor in-charge of IITM Research Park. He also chairs a MHRD committee called "Quality Enhancement of Engineering Education (QEEE)" focused on 500 Indian engineering colleges, other than IITs and NITs.

Dr. Ashok Jhunjunwala has been awarded Padma Shri in the year 2002. He has been awarded the Shanti Swarup Bhatnagar Award in 1998, Dr. Vikram Sarabhai Research Award for the year 1997, Millennium Medal at Indian Science Congress in the year 2000 and H. K. Firodia Award for "Excellence in Science & Technology" for the year 2002, Shri Om Prakash Bhasin Foundation Award for Science & Technology for the year 2004, awarded Jawaharlal Nehru Birth Centenary Lecture Award by INSA for the year 2006, IBM Innovation and Leadership Forum Award by IBM for the year 2006, awarded Bernard Low Humanitarian Award in 2009, awarded "Bharat Asmita Vigyaan –Tantragyaan Shresththa Award" for the best use of Science & Technology through Innovation in 2010, and awarded Honorary Doctorates by the Institute of Blekinge Institute of Technology, Sweden in 2008 and University of Maine, USA in 2010. In 2010, he was also awarded JC Bose Fellowship by DST, Government of India, awarded Dronacharya Award (2011) by TiE and recently awarded Top Innovator of Top 11 in 2011 Innovators Challenge. He is a Fellow of World Wireless Research forum, IEEE and Indian academies including INAE, IAS, INSA and NAS.

Prof. Jhunjunwala is a Director on the Board of Tata Teleservices (Maharashtra) Limited, Polaris, 3i-Infotech, Sasken, Tejas, Tata Communications, Exicom and Mahindra Reva Electrical Vehicles Pvt Ltd. He is also a board member of several educational institutes and Section 25 companies including BIRAC. He was a member of the Prime Minister's Scientific Advisory Committee from 2004-14.

### Dr. Gagandeep Kang

Dr. Gagandeep Kang is a Professor in the Division of Gastrointestinal Sciences at the Christian Medical College (CMC) in Vellore, India. She is the head of the Wellcome Trust Research Laboratory and the Division of Gastrointestinal Sciences at CMC.

Dr. Kang's research on paediatric diarrhoea focuses on rotavirus epidemiology, prevention and vaccine development. For molecular strain surveillance, she has built on her own work to develop a network of Indian enteric virology laboratories and the WHO Rotavirus Reference Laboratory for SEARO, all of which have resulted in insights into the epidemiology, burden and transmission of rotavirus in India. Complementary studies on gut function investigate the sequelae of enteric infections and effects on long term growth and development. Clinical research on rotavirus vaccines has led to the establishment of facilities for Phase I to Phase III studies and for support of laboratory assays for vaccine evaluation.



Dr. Kang's work has been supported by direct competitively obtained funding from the US National Institutes of Health, the Wellcome Trust, the Bill and Melinda Gates Foundation, the European Union and other international and national funding. Her work has resulted in over 200 publications, in national and international journals of high standing, and her academic contributions have been recognized, as the first woman and the first Indian to be invited to edit the prestigious Manson's Textbook of Tropical Medicine. The large body of research conducted by her group has led to practical interventions to prevent diarrhoeal disease, and continues to lay the ground work for further interventions in the form of treatment techniques and vaccines.

She holds MBBS, MD and PhD degrees from CMC and a Fellowship of the Royal College of Pathologists, London. She is an elected Fellow of the Indian Academy of Sciences, National Academy of Sciences and the American Academy of Microbiology.



### Prof. Deepak Pental



Prof. Deepak Pental, former Vice Chancellor, University of Delhi is currently professor of Genetics, Delhi University, South campus. A post graduate from Punjab University and Ph.D. from Punjab University, Prof. Pental was post doctorate fellow at University of Rutgers, USA. Plant Biotechnology and Genetics and Plant breeding are his main areas of specialization. Prof. Pental is a recipient of many awards - 'Officier des Palmes Academiques' for contribution to Research and Education by the Government of republic of France ; O P. Bhasin (2008) award for research in Agriculture; FICCI award for Science and Technology (2010). Prof. Pental is also elected member of the National Academy of Agriculture Sciences, National Academy of Sciences, Indian Academy of Sciences and the Indian National Science Academy. He is also the recipient of J.C Bose National fellowship (2009) of DST and Jawaharlal Nehru Birth Centenary visiting Fellowship (2008) of INSA. He has a large number of publications, papers and

books to his credit in addition to 5 patents.

### Dr. Dinakar Masanu Salunke

Dr. Salunke is currently the Executive Director of the Regional Centre for Biotechnology, Faridabad. After obtaining Ph. D. (1983) from Indian Institute of Science Bangalore, he carried out post-doctoral research at the Brandeis University in USA before returning to the National Institute of Immunology, New Delhi in 1988 from where he is currently on lien. Dr. Salunke's Research Interests are Structural Biology of Immune Recognition, Molecular Mimicry and Allergy. He is a Fellow of the Indian National Science Academy (2004), Indian Academy of Sciences (2001) and the National Academy of Sciences (India) (1995). Dr. Salunke is a recipient of many awards viz. GN Ramachandran Gold Medal for Excellence in Biological Sciences and Technology (2010), JC Bose National Fellowship Award (2007), Ranbaxy Research Award for Basic Research in Medical Sciences (2002), Shanti Swarup Bhatnagar Prize for Biological Sciences (2000), National Bioscience Award (1999), among others.



#### Government Nominee

### Dr. Mohd. Aslam

Dr. Mohd. Aslam is currently Advisor (Scientist 'G') in the Department of Biotechnology (DBT). He is involved in planning, coordination and monitoring of various R&D programmes in plant biotechnology and allied areas. Currently, he is handling major programmes of DBT such as Centres of Excellence in Biotechnology, Translational Research in Products and Processed from Medicinal & Aromatic Plants and Technology Development in Silk. Dr. Aslam is the Member Secretary of the Technical Advisory Committee of Centres of Excellence in Biotechnology and DBT's Expert Groups on Translational Research in Products and Processed from Medicinal & Aromatic Plants and Technology Development in Silk. He is also working as the nodal

officer in DBT for three autonomous institutions – National Institute of Immunology (NII), New Delhi; Institute of Bioresources and Sustainable Development (IBSD), Imphal, Manipur; and International Centre for Genetic Engineering and Biotechnology (ICGEB), New Delhi and also for Biotech Industry Research Assistance Council (BIRAC), New Delhi.



## Corporate Information

**REGISTERED OFFICE** : 1<sup>st</sup> Floor, MTNL Building, 9, CGO Complex,  
Lodhi Road, New Delhi-110003  
CIN:U73100DL2012NPL233152  
Website: [www.birac.nic.in](http://www.birac.nic.in),  
Email: [birac.dbt@nic.in](mailto:birac.dbt@nic.in), Tel: +91-11-24389600

**STATUTORY AUDITORS** : **M/S SAMPRK & ASSOCIATES**  
Chartered Accountants  
302, 3<sup>rd</sup> Floor, Neelkanth House  
S-524, School Block Shakarpur,  
Delhi – 110092.

**BANKERS** : **Corporation Bank,**  
CGO Complex  
Lodhi Road, New Delhi -110003.

: **State Bank of Hyderabad**  
CGO Complex  
Lodhi Road, New Delhi -110003.

**COMPANY SECRETARY** : Ms. Kavita Anandani



# Directors' Report



## DIRECTORS' REPORT

### To the Members,

Your Directors have pleasure in presenting the Second Annual Report together with Audited Balance Sheet and Income and Expenditure Account of the Company for the year ended March 31, 2014.

## 1. ABOUT BIRAC

Biotechnology Industry Research Assistance Council (BIRAC) was established as a new Public Sector Undertaking, set up as an interface agency by Department of Biotechnology (DBT), Ministry of Science & Technology, Government of India and registered on 20<sup>th</sup> March, 2012 under the Companies Act, 1956 as a Section 25 Not for Profit Company (Now a Section 8 Company under the Companies Act, 2013) to strengthen and empower the emerging Biotech enterprise, to undertake strategic research and innovation, addressing nationally relevant product development needs. BIRAC was categorized as a Schedule 'B' Public Sector Undertaking on January 10, 2014.

### VISION

*BIRAC's vision has been to stimulate, foster and enhance the strategic research and innovation capabilities of the Indian biotech industry, particularly start-ups and SME's for creation of affordable products addressing the needs of the largest section of society.*

### THE MISSION

*Facilitate and mentor the generation and translation of innovative ideas into biotech products and services by the industry, promote academia–industry collaboration, forge international linkages, encourage techno entrepreneurship and enable creation and sustainability of viable bio enterprises.*

## 2. OUR PHILOSOPHY

Keeping up with its primary mandate "to trigger, transform and tend biotech start-ups to convert innovative research in public and private sector into viable and competitive products and enterprises", BIRAC's key philosophy is to foster innovation and promote the translation of discovery and exciting new inventions to market ready technologies and products.

BIRAC during its two years of existence has made a special effort to reach out to all its stakeholders and launch special initiatives which cater to the needs of the growing enterprise and build and strengthen the Innovation Research Ecosystem for Affordable Product Development.

The focus is on inculcating and strengthening the Innovation Research culture in young entrepreneurs, start-ups and SMEs. During the year, an Academia –Industry Interface has been strengthened and systems have been put in place to encourage academic research leads to move out of laboratories through the translation phase to product development. Partnerships have been strengthened to bring together the like-minded organisations, create networks and provide synergies needed for product development.

While the attention stays focussed on affordable and social innovation, the efforts continue to create capacity and strengths to build a globally competitive Indian Biotech Enterprise.

BIRAC's effort is to empower, enable and catalyse the innovation driven biotech enterprise to fulfil the India Vision of "a US \$100 billion Biotech Industry by 2025" and create a true "Indian Bio-Economy".

Since a two year period has elapsed since BIRAC was formally launched as a not-for profit company to play a pro-active role in the emerging biotechnology industry of the country, a Strategy Meet was convened on February 5, 2014 to reflect and deliberate on BIRAC's own business model as it steps into the future. A high level group representing stakeholders from the government, industry and academia as well as BIRAC resource persons met over two days to deliberate on the evolving role of BIRAC. The wide ranging deliberations led to several important discussions which centered around - focus to deepen existing programmes and bridge the gaps that the existing programmes might have, creating a regulatory cell which can provide advice to start ups and SMEs on national and global regulations, engagement with venture funds to support the innovation pipeline, focus on new areas such as personalised medicine and

diagnostics and biomanufacturing and ensuring greater reach to the masses. It was agreed that while BIRAC should continue its focus on the strategies defined, the effort should be to engage deeply with all the stakeholders on the points addressed above.

### 3. AUDIT COMMITTEE

BIRAC is registered under Section 25 of the Companies Act, 1956 (Now a Section 8 Company under the Companies Act, 2013) as a not for profit company. It is a private limited company which is not listed on any stock exchange. The constitution of an audit committee is not applicable to the company as it is not a public listed company. However, constitution of an Audit Committee is a requirement of the DPE Guidelines on Corporate Governance. Accordingly, an Audit committee of the Board was constituted with 3 directors, two of whom were independent on 1<sup>st</sup> May, 2014.

### 4. FINANCIAL STATEMENTS

The financial statements are made on accrual method of accounting under the historical cost convention, in accordance with the accounting standards issued by Institute of Chartered Accountants of India.

### 5. RTI

BIRAC follows all necessary procedures and processes in accordance with Government Guidelines; CPIO and other details are available on its website ([www.birac.nic.in](http://www.birac.nic.in)).

### 6. MEMORANDUM OF UNDERSTANDING (MOU)

BIRAC signed a Memorandum of Understanding (MoU) for 2014-15 with the Administrative Ministry, the Department of Biotechnology (DBT), Ministry of Science & Technology as per the Guidelines issued by the Department of Public Enterprises (DPE) on March 24, 2014.

### 7. DIRECTOR'S RESPONSIBILITY STATEMENT

In accordance with the provisions of Section 217 (2AA) of the Companies Act, 1956, the Directors state that:

- a. In the preparation of the annual accounts, the applicable accounting standards have been followed along with proper explanations relating to material departures.

- b. The accounting policies selected were applied consistently. Reasonable and prudent judgements and estimates were made so as to give a true and fair view of the state of affairs of the company at the end of the financial year and of the income and expenditure of the company for that period.
- c. Proper and sufficient care has been taken for the maintenance of adequate accounting records in accordance with the provisions of the Companies Act, 1956 for safeguarding the assets of the company and for preventing and detecting fraud and other irregularities.
- d. The Annual Accounts have been prepared on a going concern basis.

### 8. CORPORATE GOVERNANCE

A separate report on Corporate Governance is annexed with this report.

### 9. AUDITORS' REPORT

M/s. SAMPRK & Associates, Chartered Accountants have been appointed as Statutory Auditors of the Company by the Comptroller and Auditor General of India for the period under review. Comments on the observation of the Auditors' / CAG are given as an Annexure to the Directors' Report and are self-explanatory and suitably explained in various Notes on the accounts.

### 10. BANKERS

Bankers are

- Corporation Bank, CGO Complex, Lodhi Road, New Delhi -110003.
- State Bank of Hyderabad, CGO Complex, Lodhi Road, New Delhi -110003.

### 11. PARTICULARS OF THE EMPLOYEES

None of the employees are drawing remuneration beyond the monetary ceiling prescribed under Section 217 (2A) of the Companies Act, 1956 read with Companies (Particular of Employees) Rules, 1975 as amended.

### 12. ABOUT DIRECTORS

BIRAC is guided by a board comprising of senior professionals, academicians, policy makers and eminent professionals from the industry. Prof. K. VijayRaghavan, Secretary, Department of Biotechnology is the Chairman of the Board and

Dr. Renu Swarup, Senior Adviser, Department of Biotechnology is the Managing Director.

The board also comprises of 4 independent directors viz. Prof. Ashok Jhunjhunwala, Professor, IIT Chennai, Dr. Gagandeep Kang, Professor & Head, Department of Gastrointestinal Sciences, Christian Medical College, Vellore, Prof. Deepak Pental, Department of Genetics, University of Delhi, Dr. Dinakar Masanu Salunke, Executive Director, Regional Centre for Biotechnology. Dr. Mohd. Aslam, Scientist 'G', Department of Biotechnology was appointed as a Government nominee w.e.f. 17.12.2013

### 13. COMPLIANCE CERTIFICATE

As per Section 383A of the Companies Act, 1956, a compliance certificate has been obtained from the Practising Company Secretary, M/s. Neelam Gupta & Associates, New Delhi. The Certificate is a part of the Directors' Report.

### 14. CONSERVATION OF ENERGY, TECHNOLOGY ABSORPTION AND FOREIGN EXCHANGE EARNINGS AND OUTGO

Statement giving the details of conservation of energy, technology absorption and foreign exchange earnings and outgo in accordance with the Companies (Disclosure of Particulars in the Report of Board of Directors) Rules, 1988 is as follows: -

#### A. Conservation of Energy

Disclosure regarding conservation of energy is not required.

#### B. Technology Absorption, Adoption and Innovation

Particulars required under Form B of the relevant rule pursuant to Section 217(1) (e) of the Companies Act, 1956 have not been given since the company has no research and development activity. However the main function of the company is supporting innovation research in the biotech industry and promoting technology management to promote adoption and transfer of entrepreneurship in all places of research.

#### C. Foreign Exchange Earnings & Outgo

The foreign exchange earnings & outgo during the year are as given below:-

Foreign Exchange Inflow in the form of Donations	Nil
Foreign Exchange outflow	
A. Database subscription	USD 73688 & GBP 7548
B. Foreign travel by employees	USD 2300
C. Entrepreneurial Development	GBP 16918

### ACKNOWLEDGMENT

The Directors wish to place on record their appreciation for the valuable guidance and cooperation extended to the Auditors, Banks, and various governmental agencies. The Directors also wish to place on record their appreciation for the sincere efforts put in by the executives and staff of the Company.

Date: 9<sup>th</sup> September 2014  
Place : New Delhi

**For and on behalf of Board**  
Prof.K. VijayRaghavan  
Chairman



# Management Discussion and Analysis Report

(Forming Part of the Directors' Report for 2013-14)



## MANAGEMENT DISCUSSION AND ANALYSIS REPORT (Forming Part of the Directors' Report for 2013-14)

### 1. INDUSTRIAL STRUCTURE AND DEVELOPMENT

The Government of India has taken several steps to provide funding focussing on high risk innovation research in biotechnology companies, particularly companies that are at an early-stage. India has made a growing investment in the sector through various mechanisms. In the National Biotechnology Strategy 2007, the blueprint for setting up of an Independent Organisation - BIRAC was spelt out. Biotechnology Industry Research Assistance Council (BIRAC) a Schedule 'B' Public Sector Undertaking was set up in March 2012 as an interface agency of the Department of Biotechnology, Ministry of Science & Technology which supports the innovation ecosystem through funding, infrastructure, capacity building and mentoring support. The focus is on strengthening and augmenting the innovation research capacities of young entrepreneurs, start-ups and SMEs. The goal is to stimulate commercialization of discoveries by funding translational research.

The overall bioscience industry, comprising of the biopharmaceuticals, diagnostics, clinical and contract research services, enzymes, bioagri, and bioinformatics recorded Rs. 23,524 crore in sales in 2012-13. India's biotechnology sector for the year ending March 31, 2014 recorded revenues of \$ 4.5 billion\*. It is striving to achieve the \$100 billion revenues in 2025.

India's biopharmaceutical sector is a world leader in vaccines producing 60 percent of the world's supply. Some 15 companies produce more than 50 brands, according to the India Brand Equity Foundation. Vaccines represent the strongest generators of revenue within India's biopharmaceutical sector and the industry has shown its ability to both innovate and provide cost-competitive products to meet global demand.\*\*

India, long associated with its strengths in generic drug and active pharmaceutical ingredient manufacturing, is also demonstrating that it is capable of creating innovative biologics. The emerging area of biosimilars promises to increase access and affordability to life-improving and life-savings medicines in India, as well as provide a global growth opportunity for Indian biopharmaceutical companies. The emerging market

for biosimilars is attracting not only leading Indian biopharmaceutical companies, but generic drug makers as well. Though these drugs will be able to command higher prices than generic small molecule drugs, it will be a competitive market and likely to contribute less than 5 percent of the \$100 billion goal by 2025, suggesting innovation will be critical to driving growth.

### 2. STRENGTH AND WEAKNESSES

The National Biotechnology Development Strategy (NBDS) announced by the Department of Biotechnology, Government of India in 2007 stated its vision as "To use powerful tools of biotechnology to help convert the country's diverse biological resources to useful products and processes that are accessible to its masses for economic development and employment generation". During its two years of existence, BIRAC has made a special effort to reach out to all its stakeholders and launch special initiatives which cater to the needs of the growing Enterprise and build and strengthen the Innovation Research Ecosystem.

### BIRAC'S KEY STRATEGIES

- Foster innovation and entrepreneurship in all places of research
- Promote affordable innovation in key social sectors
- Higher focus on start-ups & small and medium enterprises
- Contribute through partners for capability enhancement
- Encourage diffusion of innovation through partners
- Enable commercialization of discovery
- Ensure global competitiveness of Indian enterprises

### ARE CLOSELY ALIGNED TO THESE GOALS

- India's Science & Technology Policy over the years has laid strong emphasis on promotion and cultivation of scientific research and innovation.
- The 1<sup>st</sup> Scientific Policy Resolution (SPR) of 1985 resolved to "Foster, promote and sustain the cultivation of scientific research" in all its science.
- The Technology Policy Statement (TPS), 1983 emphasized on the need to attain technology competence and self-reliance.

\*BioSpectrum Volume 2 Issue 7<sup>th</sup> July 2014

\*\* Annual Biospectrum ABLE Survey Accelerating Growth: Forging India's Bioeconomy

- The Science & Technology Policy (STP) 2003 brought Science & Technology together and emphasized on the need for investments in R&D.
- The Science & Technology Innovation Policy (STIP), 2013 reemphasized the need to promote science and technology, enhance investments in research & development - both private and public and create an ecosystem for science and technology and innovation.
- The policy states that "the guiding vision of aspiring Indian STI enterprise is to accelerate the pace of discovery and delivery of science led solutions for faster, sustainable and inclusive growth.

### 3. RISK AND GOVERNANCE

In 2007, India released its National Biotechnology Development Strategy, which recognized the industry as a "sunrise sector" in need of "focused attention."

The policy called for greater coordination between ministries, funding for innovative R&D projects in small and medium-sized companies and efforts to enhance the strength of the life sciences within its academic institutions. In addition, it supported new centers of excellence for biotechnology, the development of new incubators and biotech parks and testing and lab facilities. India has made a steadily growing investment in the sector through various mechanisms. It has also taken other steps to encourage investment and ease financial pressures on biotechnology companies, such as subsidies and tax breaks for R&D spending.

Though each sector within India's biotechnology industry faces unique issues, there are also common sources of strength and common obstacles that threaten to stunt its growth. To realize its vision as an innovation-driven \$100 billion bio economy by 2025, it is important to strengthen connections between the academic and industrial sectors, increase available investment for early-stage biotechnology companies, and encourage more R&D spending.

BIRAC's key strategies are aligned in a manner that the attention stays focused on Promoting Partnerships "to encourage Innovation Research for Affordable Product Development".

This includes inculcating and strengthening the Innovation Research Culture in young entrepreneurs, start ups and SME's. For this to happen effectively, the academia - industry interface has been strengthened and systems put in place to encourage academic

research leads to move out of laboratories, through the translational phase to product development. "Partnerships" are the key to success - partnerships between academia and industry, between industry consortia, between national and international research groups and industries and also between Innovation-funding and development agencies - national, global, government, philanthropic and corporate houses.

## 4. FOSTERING INNOVATION AND REDUCING 'INNOVATION RISKS'- PROMOTING ENTREPRENEURSHIP

### 4.1 BIOTECHNOLOGY IGNITION GRANT (BIG)

BIRAC believes that the "bio-innovation capital" of the nation would come from novel ideas which have a commercialization potential and that evolve out from start-ups or academic spin-offs. BIRAC's strategy is therefore to support the numerous exciting ideas which have an unmet need for funding and mentorship. This strategy is fulfilled through a grant funding scheme called Biotechnology Ignition Grant (BIG) which is available to scientist entrepreneurs from research institutes, academia and start ups. The Applicant must be either an Incubatee or have a registered company with a functional R&D laboratory to be eligible for this grant. The scheme is designed to stimulate commercialization of research discoveries by providing very early stage grants to help bridge the gap between discovery and invention.

The purpose of the BIG Scheme is to foster generation of ideas with commercialisation potential, upscale and validate proof of concept, encourage researchers to take technology closer to the market to a startup and stimulate enterprise formation. The call for proposal is announced twice every year, on 1<sup>st</sup> January and 1<sup>st</sup> July. As part of this scheme, successful BIG Innovators receive up to INR 50 lakh (approx. \$100K) for research projects with commercialization potential with duration of up to 18 months.

The BIG Scheme is currently managed through 5 BIG Partners across the country viz. IKP Knowledge Park, Hyderabad, Centre for Cellular and Molecular Platforms (C-CAMP), Bangalore, Foundation for Innovation and Technology Transfer, New Delhi, KIIT Technology Business Incubator, Bhubaneswar and Venture Center (Entrepreneurship Development


Center), Pune, who work with the Ignition grantees (BIG Innovators) to provide mentoring, monitoring, networking and other business development related activities.

BIG Partners provide various platforms for BIG Innovators viz. mentoring and handholding for activities related to IP Management, legal and contract, mobilizing resources and other business development related activities to all recipients of Biotechnology Ignition Grant (BIG Innovators), organizing workshops/ seminars/ mentoring sessions for the BIG Innovators, providing a platform for interaction with senior experts and other academic partners and organizing a one time mentoring session or pre graduation ceremony just before the completion of the selected projects.

The First Batch of BIG would be graduating in Aug-Sept 2014, and BIRAC provides various on-going and future activities for supporting them further.

BIRAC has announced four calls as of March 2014. The table below provides an overall status of the BIG scheme.

BIG Call	I	II	III	IV
Date of Launch	1.06.2012	1.1.2013	1.7.2013	1.1.2014
Number of proposals received	133	156	176	178
Total number of proposals recommended by BIG Partners	40	58	63	75
Projects Approved	19	20	26	31 recommended and Under Due Diligence



## 1<sup>ST</sup> CALL BIG VALEDICTORY MENTORING PROGRAMME, 17<sup>TH</sup>-18<sup>TH</sup> JUNE 2014

Centre for Cellular and Molecular Platforms (C-CAMP), a Department of Biotechnology initiative, is one of the partners of BIG and as a part of C-CAMP's Mentorship Program, C-CAMP held its first Valedictory program for the 1<sup>st</sup> call awardees on the 17<sup>th</sup> and 18<sup>th</sup> of June 2014. Through the first round of BIG (started late 2012), C-CAMP's 6 start-ups/entrepreneurs have successfully progressed their innovative ideas towards proof-of-concept studies.



**BIG I Valedictory Mentoring Program 2014 at C-CAMP**

### A. C-CAMP'S BIG GRANTEES VALEDICTORY DINNER - DINING WITH CZARS:

Of the 2 events planned, one was 'Dining with Czars', an exclusive dinner hosted by Dr. Kiran Mazumdar Shaw. The objective of this event was to have the awardees interact with a successful industry icon and learn from their experiences.

### B. C-CAMP'S BIG GRANTEES MENTORING PROGRAM:

The second event scheduled was the mentoring program held at C-CAMP with experts from academia and industry, many of whom have had the experience of supporting innovation in various forms like in academia, industry and starting companies of their own.

## 4.2. BIO INCUBATORS SUPPORT SCHEME (BISS)

In order to foster techno entrepreneurship in biotechnology, BIRAC has provided support for strengthening and upgradation of the existing Bioincubators and also to establish new world class Bioincubators in certain strategic locations like Universities/Institutes/Biotech Parks and SEZs. These Bioincubators provide the incubation space and other required services to start-up companies for their initial growth.

Thirteen existing incubators around the country including one world class, state of the art national Bioincubator at Faridabad Bio-cluster have been supported and strengthened by BIRAC's well-structured funding and mentoring support. Approximately 1,24,000 Sq. Ft. incubation space has been created. A BIRAC Bioincubator provides support for:

Establishing incubator space for Start-ups and Entrepreneurs which includes

- Lab space: 200 Sq.ft; 300 Sq.ft, 500 Sq.ft
  - Bench space: Half/full bench
  - Office space
  - Creating Specialized facility
  - Plant growth
  - Quality Testing
  - Microbial fermentation
  - Access to a pool of special equipments in the Central Equipment Facility.
  - Connect and facilitate Industry-Academia Interaction for both smooth flow of knowledge from Academia to Industry and also for providing the required Technical Mentorship.
- a. Enabling services and required mentorship for:
- a. Intellectual Property Rights (IPR)
  - b. Legal Consultations
  - c. Business Mentoring



- d. Other Consultancy Services
  - e. Other Funding Support
  - f. Resource mobilization and networking platform.
  - g. Other services
- b. Relevant Manpower required to run the Bio-incubator

**Table of Bioincubators**

	Incubator	Target Location	Incubation Space (In Sq. Ft)
1	IKP, Hyderabad	Stand Alone Park/Bio Park	3000
2	SBTIC, Hyderabad		3550
3	GSBTM, Savli		14090
4	KSIDC, Trivendrum		3000
5	RCB Bio Cluster, Faridabad, Phase I	Biotech Cluster	55000
6	FITT, IIT Delhi	Indian Institute of Technologies	3500
7	SIDBI, IIT Kanpur		7000
8	IIT Madras		10000
9	C-CAMP, Bangalore	Universities/Research Institutes	3000
10	ZTM-BPD, IARI, Delhi		3000
11	KIIT-TBI		8000
12	NCL, Pune		6000
13	PERD, Ahmedabad		5000
	Total		124140

9 Bioincubators are fully operational, a total of 49 incubatees are currently incubated and 12 incubatees receive guidance or are virtual incubatees.

**4.3 UNIVERSITY INNOVATION CLUSTERS (UIC)**

BIRAC has developed a focused strategic action plan to foster the culture of innovation and techno-entrepreneurship in Indian Universities, leveraging the experience ground through the Cluster Innovation Centre (CIC) model created by the National Innovation Council (NIC). This is an innovation support program for Universities to proactively create vibrant ecosystems that can seed, foster and nurture innovation at young entrepreneurs level.

Five University clusters as mentioned below have been identified to establish Cluster Innovation Centres in Biotechnology (CIC-B):

1. Anna University, Chennai
2. Punjab University, Chandigarh
3. Tamil Nadu Agricultural University, Coimbatore

4. University of Rajasthan, Jaipur
  5. University of Agricultural Sciences, Dharwad
- Cluster Innovation Centre in Biotechnology (CIC-B), hosted in these Universities will be facilitating the creation of networks and partnerships between stakeholders. To strengthen the innovation ecosystem, the CIC-B is providing pre-incubation support to young student entrepreneurs to take forward their innovative ideas for effective translation into products thereof.

**UIC SUPPORT INCLUDES:**

- A Cluster for 5-6 students/young Entrepreneurs to test their ideas/discoveries and take them to Proof of Concept
- An incubation space-2500-3000 Sq.ft;
- BIRAC Innovation Fellowships for two (2) Post Docs. and four (4) Post M.Sc. Fellows per university



- BIRAC Innovation Grant:
  - ◆ Post Doc. Fellow: BIRAC Innovation Fellowship @ Rs. 50,000/- p.m. & Innovation Grant of Rs. 5,00,000 p.a. for three years
  - ◆ Post M.Sc. Fellows: BIRAC Innovation Fellowship @ Rs. 30,000/- p.m. & Innovation Grant of Rs. 2,00,000 p.a. for three years
- Industry Participation for training, mentoring, sponsored research and networking opportunities and IP & Technology Management, access to risk finance among others.

#### 4.4 BIRAC REGIONAL INNOVATION CENTRE

IKP Knowledge Park has partnered with BIRAC in 2013 to set up the BIRAC Regional Innovation Centre (BRIC) at IKP to advance the mandate of BIRAC in southern India through deeper engagement with life sciences based organizations in the region.

BRIC has the following three mandates:

##### A) MAPPING REGIONAL INNOVATION ECOSYSTEM

- Covering of RIS mapping at regional areas Andhra Pradesh, Karnataka, Tamil Nadu and Kerala, which would include mapping of key stakeholders in the specified region including R&D Institutions, Companies, Associations / Professional groups with regard to areas of expertise.
- RIS Mapping of the Hyderabad region has been completed

##### B) IP AND TECHNOLOGY TRANSFER CELL

- The IPR and Technology Transfer Cell will undertake a study on the demand and supply of technologies in the AP Pharma cluster and develop an online database of technologies for in and out licensing.
- IP & Technology Transfer Cell will carry out preliminary technology evaluation and competition mapping so that right technologies can be showcased.

##### C) ENTREPRENEURIAL CAPACITY BUILDING

- Helping to build commercially viable technologies and spinouts from research organizations: BRIC will devise suitable mechanisms to help researchers and faculty

to commercialize their innovation, either by forming spinoffs themselves or by employing teams who can accelerate the process.

- Fostering Entrepreneurship in R&D institutes and Colleges

#### EMPOWERING ENABLING & DRIVING THE INDIAN BIOTECH INNOVATION ECOSYSTEM FOR AFFORDABLE PRODUCT DEVELOPMENT:

BIRAC supports affordable product development by empowering and enabling Indian biotech innovation ecosystem through its funding schemes. BIRAC's innovation funding schemes encourage collaboration between the two important stakeholders of biotech ecosystem i.e. industry and academia and provide a conducive environment for collaborative R&D by supporting all major areas of biotechnology sector i.e. Healthcare, Agriculture and Industrial biotechnology.

BIRAC's maximum funding support, till date, was given to the healthcare sector covering the areas of Drugs (including drug delivery), devices/diagnostics, biosimilars and vaccines/clinical trials. Agriculture sector covers MAS, RNAi, Transgenics and soil health management whereas Industrial biotechnology includes industrial products/processes and secondary agriculture.

BIRAC monitors and mentors its funded projects through thematic reviews in the areas mentioned above, identifies the gaps and chalks out its future course of action accordingly.

BIRAC schemes cover all aspects of the discovery-development pipeline i.e. from idea generation to commercial scale production. As of March 2014, 143 projects were ongoing and 21 out of them are collaborative projects from BIRAC's flagship schemes i.e. SBIRI and BIPP.

##### Major Accomplishments

Category	Accomplished Number
Products	06
Technologies	07
Process	02
Early stage technologies	16
IP generated	04
IP facilitated	02

## 5.1 SMALL BUSINESS INNOVATION RESEARCH INITIATIVE (SBIRI)

SBIRI boosts early stage, innovation focussed Public Private Partnership (PPP) initiative in the area of biotechnology. This scheme was launched in 2005 by DBT and is presently managed by BIRAC. The maximum funding support from this scheme was provided to healthcare followed by industrial biotechnology and agriculture sectors. As of March 2014, 76 projects were ongoing with 12 of them as collaborative projects. Three calls were announced in 2013-14 and seven proposals were committed funding of Rs. 335 lakhs as BIRAC contribution and Rs. 254 lakhs as company contribution. During 2013-14, the accomplishments from this scheme include one product in healthcare, one process in agriculture, four early stage technologies that are ready for further validation and one patent in the area of industrial biotechnology. The product, Fibro Heal, already in use for burn wound management at AIIMS is a face mask and was developed based on silk protein. The process for generating stable saline tolerant cytoplasmic male sterile lines of rice was developed utilizing marker assisted selection. The early stage technologies are for healing auto graft/diabetic wounds, diagnosing tuberculosis, smart drug delivery systems and for the production of 'Thermomyceslanuginosus (TL)' lipase on 100 L scale. The patent is process for the production of 1, 3 - propanediol from biodiesel waste glycerol.

## 5.2 BIOTECHNOLOGY INDUSTRY PARTNERSHIP PROGRAMME (BIPP)

BIPP partners with industries for support on a cost sharing basis for path-breaking research in frontier futuristic technology areas having major economic potential. The scheme accelerates the commercialization of new indigenous technologies in the key sectors of biotechnology. It was launched in 2008 and thirty calls were announced till date. As of March 2014, 67 projects, with 9 projects having industry/academia collaborations, were ongoing with BIRAC contribution of Rs. 84.69 crores of which Rs. 21.11 crores was as grant and Rs. 63.58 crores was as loan with an equal contribution from the company.



*Fluorescence reader for point of care diagnostics*




*'AINA' device*



*PDT Laser System*

Three calls were announced in 2013-14 and 20 projects were committed funding of Rs. 52.91 crores of which Rs. 11.99 crores is as grant and Rs. 40.92 crores as loan by BIRAC, with companies committed contribution of 55.42 crores.



*Hepatotoxicity prediction platform*

BIPP scheme accomplished five products, seven technologies, one process, twelve PoCs and three patents during the year 2013-14. The product for the detection of multiple infections in remote settings, the device for the diagnosis of diabetes and PDT laser



*(a) Technology Platform for production of biological hydrogen*

*(b) Pilot Plant for production of 3000 Litre ethanol per day*

system for cancer treatment are some of the products developed under BIPP. Few of the technologies include hepatotoxicity prediction platform for increasing efficiency of drug development, production of viable

enzymes from agro waste and nano-composites for micronutrient & pesticide delivery. Process for the single step extraction of cottonseed with micelle refining was developed under BIPP in the current year. The PoCs include early stage technologies from all three important sectors of biotechnology. HDAC inhibitor for cancer therapy, Anaerobic Membrane Bioreactor (AnMBR) for waste to energy solution and identification of QTL(s) for drought tolerance are some of the PoCs which have resulted from BIPP to name a few. The patents filed under BIPP are in the areas of drugs and devices/diagnostics.

In addition, protein characterization facility for high end analytical testing was created under this scheme.


### 5.3 CONTRACT RESEARCH AND SERVICES SCHEME (CRSS)

CRSS provides opportunity to academia to involve industry for translational research and product development towards commercialization. The striking features of this scheme are IP resides with academia and funding will be in the form of grant-in-aid. The scheme was introduced in 2012 and funding support was provided to all key areas of biotechnology sector. The number of ongoing projects as of March 2014 is 9 at a total cost of Rs. 248 lakhs as BIRAC support. The total number of academia supported within this period is 11 with 9 partnering companies.

Two calls were announced in 2013-14 and five proposals with five academia & five partnering companies were committed for funding of Rs. 650 lakhs.

The following are few of the proposals supported under this scheme,

- Design of Peptidomimetics following in-silico approaches and to test their efficacy in clearing beta amyloid load by ex vivo model of Alzheimers disease'



- Validating the rapid diagnostic method for the detection of HLA allele and associating it with cutaneous drug reactions with epilepsy.
- Discovery of genome-wide SNPs and its use in developing a reference linkage map and association analysis in castor



**Association Mapping Panel of Castor**

- Validation of serological diagnostic kits for testing of plant viruses affecting horticultural crop.
- The identification and development of aza-Flavanones and triazole derivatives as new anti-cancer agents
- Developing a bioreactor system for production of laccase and verification of commercial viability of the process

### 5.4 PARTNERSHIP WITH CDSA FOR MANAGEMENT OF BIRAC SUPPORTED CLINICAL TRIALS

BIRAC has partnered with Clinical Development Services Agency (CDSA) to strengthen its capabilities in project management related to clinical trials and regulatory requirements. According to this partnership, CDSA has to provide technical advice in the areas of pre-clinical/clinical development, ensure quality for BIRAC funded projects and training of potential investigators. The role of BIRAC is to provide necessary support to CDSA to undertake these activities. As part of this partnership, CDSA offers the following specific expertise a) Review of clinical study protocol and other related documents b) Clinical site assessment and c) Audit for clinical studies of drugs, devices, biologicals and vaccines.


BIRAC has already completed the formalities and initiated activities under this partnership.



## 5.5 SOCIAL INNOVATION PROGRAMME FOR PRODUCTS: AFFORDABLE & RELEVANT TO SOCIETAL HEALTH (SPARSH): TOUCHING A BILLION LIVES

The programme highlights the need for innovative solutions to society's most pressing social problems.

The scheme tackles major social issues and offers new ideas for wide-scale change. The scheme aims to invest in ideas and innovations that improve health care of all Indians and provide affordable product development in social sector.





The scheme also has a component of Social Innovation Immersion Program (SIIP) which is for creating a pool of social innovators in the biotech arena who will identify the specific needs and gaps in healthcare. The social innovators will be supported for developing market-based solutions that has potential to bring health care breakthroughs to the vulnerable population.

### THE OBJECTIVES OF THE PROGRAM ARE:

1. Identify and provide support to cutting edge innovations towards affordable product development that can bring significant social impact and address challenges of inclusive growth.
2. Provide support in the form of impact funding to biotech product innovations (with social goals) that can be scaled.
3. Create and foster a pool of social innovators in biotech and provide a platform to share best practices and understand intricacies of business models in social innovation and network.

SPARSH was launched on 15<sup>th</sup> Aug 2013, with focus on Maternal and Child Health. The first call aimed to foster biotechnology innovation research for affordable product and solutions in national priority area - Maternal & Child Health (MCH). The call was aligned with the UN Millennium Development Goal 4 and 5 i.e. Reducing Child mortality and improving Maternal Health.



112 Letters of Intent (Lols) were received under the first Call of SPARSH. These Lols have undergone a rigorous evaluation process comprising of SPARSH Technical Advisory Group meetings and site visits. Finally, 16 proposals were funded. 10 proposals are from Category A for establishing Proof of Concept. One proposal is for validating the existing technology and five proposals are from Social Innovation Immersion Program (SIIP) for Immersion fellowship.



## 6. BUILDING STRATEGIC ALLIANCES

### 6.1 GRAND CHALLENGES INDIA: DBT-BIRAC-GATES FOUNDATION

Department of Biotechnology (DBT), Ministry of Science and Technology of India and the Bill & Melinda Gates Foundation (BMGF) signed a Memorandum of Understanding to collaborate in scientific and technological research to alleviate some of the world's most critical global health and development issues over a period for the benefit of people in India and developing countries worldwide. BIRAC, the primary fiduciary agent and management unit for executing the partnership between DBT and BMGF, acting as implementing agency through Program Management Unit (PMU) launched the Grand Challenges India (GCI) to support initiatives that could dramatically change the health and development landscape in India and other countries facing similar challenges. Specifically, it identifies the following priorities for cooperation:

1. Reduction of maternal and child mortality and morbidity;
2. Scientific and technical solutions for infectious diseases;
3. Strengthening India's scientific translation capacity;
4. Scientific and technical advances related to agriculture;
5. Scientific advancement in food and nutrition;
6. Other joint interests that may arise.

First funding scheme under Grand Challenges India (GCI) Program announced "Achieving Healthy Growth through Agriculture and Nutrition" as the first initiative. The awards were announced on BIRAC 2<sup>nd</sup> Foundation held on 20<sup>th</sup> March, 2014 by Prof. K. Vijay Raghavan, Secretary DBT & Chairman, BIRAC. The 5 proposals which were selected focussed on the development of innovative intervention that integrates agriculture practices with nutrition outcomes linking to improved health benefits of woman and children for significant socio-economic impact. Two Interventional Development Grants and Three Seed Grants were awarded.

The second initiative to "Reinvent the Toilet Challenge" was launched with the aim to catalyse innovative and sustainable solutions for improved sanitation facilities and production of next generation toilets and expanding access to sanitation to under-served populations in India. The first global Reinvent the Toilet Fair (RTTF) was to showcase the measurable

advancement that the foundation's grantees and accomplices are making towards the objective of "Reinventing the Toilet", which supplemented by proper interest side exercises, can help give billions of individuals worldwide with sheltered and moderate access to sanitation. The fair was co-hosted by the Department of Biotechnology and the Bill & Melinda Gates Foundation. The fair was additionally backed by other key Government of India services including the Ministry of Urban Development and the Ministry of Housing & Urban Poverty Alleviation.

On 22<sup>nd</sup> March 2014, at 'Reinvent the Toilet Challenge – India Fair', the shortlisted applicants were honoured award letters. Six Indian innovators with Indian and global collaborations were awarded under the call; one proposal in Field Trial Grant and 5 proposals in Proof of Concept Grants.



*Awardees of Grand challenges India "Re-invent the Toilet Challenge, India" along with senior officials from DBT, BIRAC & BMGF*


### 6.2 TEKES

TEKES, is one of the most prominent publicly funded expert organisation for financing research, development and innovation in Finland. TEKES promotes a broad-based view on innovation besides funding technological breakthroughs while emphasizing the significance of service related, design, business, and social innovations.

BIRAC, along with DBT had partnered with TEKES to promote joint cross border resource mobility, which is aimed to enhance the collaborations in the field of technology and innovations and enable the development of affordable technologies and products for the common challenges faced by both the countries. As a part of this initiative, 5 BIRAC supported fellows attended the three day 'Indo-Finnish Workshop on Health and Well-being' during 10<sup>th</sup> -12<sup>th</sup> September, 2013, at Helsinki, Finland. The Indian participants highlighted that they have initiated some strategic partnerships with Finnish organizations in areas of common interest.

### 6.3 CEFIPRA

This challenge-oriented program was implemented by the Indo French Centre for Promotion of Advanced Research (CEFIPRA) with joint funding from Biotechnology Industry Research Assistance Council (BIRAC), Government of India and the Science and



Technology Department (S&T Dept.) of the French Embassy in India, Ministry of Foreign Affairs, Government of France. In this collaboration, BIRAC will support Indian partners and the French Embassy will support French partners.

BIRAC and CEFIPRA have signed a Memorandum of Understanding (MoU) to support Indian and French biotech start-ups and SMEs for promoting the innovation ecosystem in both the countries. French Embassy in India, CEFIPRA and BIRAC have committed to support challenge oriented high-quality bilateral innovative research projects towards new concepts and technological breakthroughs in human health. The partnership aims to improve the competitiveness of both Indian and French biotech industries and academia. The first call for proposals announced on 20<sup>th</sup> March, 2014 is on Cardiac stroke, Alzheimer and Gerontology.

### 6.4 WELLCOME TRUST

The Wellcome Trust and BIRAC signed a Memorandum of Understanding (“MOU”) on 19<sup>th</sup> March 2014 to operationalize a joint funding call to support companies and not-for-profit entities to develop innovative healthcare products at affordable costs. The aim of the joint call is to conduct a funding round to bring together researchers largely working in India, to develop innovative, safe and effective healthcare products at affordable costs. The MoU sets out the various operating guidelines which have been agreed between the Trust and BIRAC in respect of the activities



*Dr. Ted Bianco, Director-Innovation, Wellcome Trust and Dr. Renu Swarup, MD, BIRAC signing the MoU in the presence of Prof. K. VijayRaghavan, Secretary, DBT and Chairman, BIRAC*

to be undertaken (and related costs to be incurred) to establish and operate the Joint Call. The total budget for awards under the joint call is up to two million pounds sterling (£2,000,000) or the equivalent in Indian Rupees (INR ~20 Crore). The current Joint Call under the theme: “Diagnostics for Infectious Diseases” was announced to the public on 21<sup>st</sup> March 2014.

### 6.5 THSTI-BIRAC-WHO

BIRAC in partnership with policy unit THSTI was involved in an Agreement for Performance of Work (APW) with WHO-SERO, New Delhi, India for a study entitled “A study to suggest methodologies to develop norms and standards for classification of health R&D needs of developing countries”, as a follow-up of the CEWG recommendations during WHA 65. Under this APW both BIRAC and Policy Unit THSTI identified methodologies to develop norms and standards for classification of health R&D needs of developing countries based on systematically collected and collated information from India.

Under this APW, an observational study was done on the Indian Government's fund allocations/ expenditure in health R&D. A detailed analysis and comparison of resource flow on R&D by various Indian biomedical funding agencies assisted in identifying the critical need and gaps important for implementing the specific actions and recommendations. The recommendations made would be useful to CEWG in delineating the global strategy and plan of action on public health, innovation and intellectual property. India has a diverse epidemiology and it is hoped that these recommendations would help the SEA region member countries to outline methodologies to develop norms and standards for classification of health R&D needs for developing countries.



## **7. TECHNOLOGY TRANSFER AND ACQUISITION**

### **7.1 BIRAC – QUT AUSTRALIA - BIO-FORTIFICATION AND DISEASE RESISTANCE IN BANANA**

Queensland University of Technology, Australia has developed bio-fortified banana under the Grand Challenges in Global Health Program to alleviate vitamin A and iron deficiency. An Agreement signed between BIRAC and Queensland University of Technology (QUT), Australia for “Development and Transfer of Technology from QUT, Australia to India for Bio-fortification and disease resistance in Banana” in August, 2012 was the initiation of an important technology transfer.

This Agreement not only aims to share the knowledge, experience and achievements of Queensland University of Technology (QUT), Australia but also to develop, validate and transfer the two specific traits in two banana varieties cv. Grand Nain and Rasthali.

The Technology Transfer for Bio-fortified Banana from QUT, Australia is to 5 Indian Partners

1. National Agri-Food Biotechnology Institute, Mohali, Punjab
2. National Research Centre for Banana, Trichy, Tamil Nadu
3. Bhabha Atomic Research Centre, Trombay, Mumbai
4. Tamil Nadu Agricultural University, Centre for Plant Molecular Biology & Biotechnology, Coimbatore
5. Indian Institute of Horticultural Research, Bangalore, Karnataka

During the period April 2013 to March 2014, there has been successful transfer of Gene Cassettes and establishing of suspension cultures with the Indian partners. This was reviewed and mentored by the QUT Team by visiting individual partners. A work shop was also held at NABI in September 2012, where the transgenic tracker software from QUT installed at NABI and the review of the work done by the partners was discussed in detail.

## **8. SUPPORTING THE INNOVATION ECOSYSTEM**

### **8.1 INTELLECTUAL PROPERTY (IP) CELL**

#### **8.1.1 IP & TECHNOLOGY MANAGEMENT SUPPORT: SAFEGUARDING THE INDIAN BIOTECH INNOVATION**

BIRAC's in-house IP cell provides support to academia, start-ups, industries and SMEs on various aspects of IP such as on Patent Landscaping, Patent Filing & drafting and Freedom-To-Operate. BIRAC undertakes an extensive IP due-diligence of proposals that are submitted under its funding programmes such as BIPP, CRSS, SBIRI, SPARSH, Grand Challenge India (GCI), and BIG. In addition, BIRAC IP Cell provides clarity on many of the IP issues in collaborative projects including international projects.

In order to enhance the proportion of Life science invention coming out of public institutes that can be translated, BIRAC has initiated technology mapping of DBT institutes. In addition to the above activities, BIRAC IP & Technology Management cell organises various capacity building workshops/ conferences on IPR for Biotech Industry, Entrepreneurs, Start Ups, Students etc. for empowering them to create a better IP strategy.

The assistance provided by the IP cell includes a) prior art searches / FTO searches for projects received under the funding schemes like BIPP, CRSS, BIG, SBIRI etc. b) prior art search/ FTO search/ Landscape for other national/international projects c) patent landscape analysis d) support for patent drafting and filing under Patent Assistance Funding Scheme (PAFS) for SMEs, Start-ups, Academia and industries through empanelled IP law firms e) technology mapping for DBT institutes f) DBT-ICT centre for IP & Technology Transfer activities and g) IP Manager.

#### **8.1.2 PATENT ASSISTANCE FUNDING SCHEME**

BIRAC has started a Patent Assistance Funding Scheme (PAFS) for Intellectual Property protection to encourage technological innovation in the country and to support the entrepreneurs, industries and SMEs. BIRAC received requests from BIRAC scheme beneficiaries (BIG, SBIRI and BIPP) and has supported industries and academic institutions to protect their intellectual property rights. A total of two patents have been supported through the Patent Assistance Funding Scheme (PAFS). These patent applications are filed mainly in the area of secondary agriculture and healthcare.

### 8.1.3 DBT-ICT CENTRE FOR IP & TECHNOLOGY TRANSFER ACTIVITIES

BIRAC has also set up an IP Management and Technology Commercialization (IPM-TC) unit at DBT-ICT Centre for Energy Bio-Sciences at Mumbai and intends to set up similar centres in different institutes which can provide competent IP services to the local ecosystem in India.

Specific objectives of the Centre are:

- Protecting the technologies generated at the centre which has commercial potential
- IP Management with regard to technology transfer, drafting MoUs and other relevant agreements
- Generating awareness related to IP protection within and outside the Centre, assistance on IP related issues within ICT and outside ICT.

DBT-ICT IPM-TC Unit has filed more than 20 Patent applications at the Indian Patent Office out of which 3 patent applications have entered the national phase of many countries such as US, EP, AU, JP, Pakistan, Korea etc. IPM-TC Unit has also carried out patentability searches for more than 30 projects and has signed MoUs, CDA with Industries to take the research forward.

### 8.2 REGULATORY FACILITATION

BIRAC has an In-house Regulatory facilitation Cell which examines and ensures compliance of the BIRAC funded proposals with Regulatory guidelines of India. The Cell draws upon the expertise of Regulatory experts from Central Drugs Standard Control Organization (CDSCO), ICMR and other experts from medical institutes and industries. The mandate of the Regulatory cell is to address the queries and build capacities of SMEs, Young Entrepreneurs, Academic institutes and start ups on issues related to the regulatory compliance of Product Approvals.

#### Workshops

Under the Capacity Building mandate, BIRAC in collaboration with Clinical Development Services Agency (CDSA) has planned to organise a set of four Regulatory Workshops under the series “Demystifying Indian Drug regulations for Product Approvals” in North and South India.

The first two workshops in first phase in North has already been organised on Regulations of “New drugs” and “Biopharmaceuticals”. Around 200 participants have benefited from these regulatory events.



*Regulatory Workshop on Biopharmaceuticals*

#### The Regulatory Workshops focus on topics like:

- Updates on Indian Regulations, Guidance and Laws in India
- Understanding the Drugs and Cosmetic Act, India
- The format and content of IND submissions including regulatory and scientific requirements
- Pre-Clinical and Clinical Documentation Needs
- Review & Approval Process
- Real time Experience in Filing and seeking Approvals for INDs

### 8.3 LEGAL ADVISORY SUPPORT

BIRAC's Legal and Contracts Cell provides a complete due diligence required for all legal activities of the organisation and its programmes including formulation and execution of various research funding schemes, technology transfer, licensing agreements, contract research, MoUs, agreements between BIRAC and its partnering organisations. The Cell also extends its support to the industry as per their needs on a case to case basis.

The Legal and Contracts Cell opines on related issues and has standardized the templates for different PPP models of support to Company, Consortium, Technology Transfer, Collaborative Programmes between Industry and Academia etc.

## 9 NETWORKS & MISSIONS

### 9.1 BIRAC FACILITIES FOR TRANSLATION RESEARCH

#### 9.1.1 EARLY TRANSLATIONAL ACCELERATOR (ETA)

BIRAC's mission is to facilitate translation of innovative ideas into biotech products and as a part of meeting this objective, BIRAC conceptualized Early

Translational Accelerator (ETA) which identifies early academic discoveries with possible commercial and societal impact and processes them to industry ready technologies. Very few of many exciting discoveries from academic labs see the light of the day in terms of being commercialized, as these kind of accelerators do not exist in the current Indian setting.

BIRAC proposed to set up ETAs at different places in the country and to consider discoveries from healthcare, agriculture and industrial biotechnology sectors for validation. BIRAC has funded Early Translational Accelerator to C-CAMP as part of this initiative which is expected to be functional shortly in the area of healthcare.

## 9.2 NICHE AREA MEETINGS

BIRAC organizes discussion meetings in niche areas to identify the requirements and to formulate strategies accordingly. The following meetings were organized as part of this initiative.

### a) Human PapillomaVirus (HPV)

Human papillomavirus (HPV) infection is the leading cause of cervical cancer, which in turn is the leading cause of cancer-related mortality in women. BIRAC has performed a mapping exercise on the current status of HPV infection and organized a “Discussion Meeting on Human Papilloma Virus: Strategies for New Therapeutic Interventions” by inviting experts from academia, industry and government agencies to understand the current needs of addressing HPV infection.

By considering the recommendations of experts, BIRAC decided to announce a special call on ‘HPV Prevention and Control’ through its Biotechnology Industry Partnership Program (BIPP) scheme inviting proposals in the areas of Screening, Diagnostic tests, Vaccines and Therapeutics.

### b) Waste to Energy

BIRAC organized a discussion meeting on “Employing bio-chemical tools for conversion of solid and liquid waste to energy” which was attended by eminent experts from industry and academia working to provide solutions for the conversion of municipal solid and liquid waste to energy and biochemical.

It was recommended that BIRAC to take initiative to promote research and development and set up demonstration plants for technologies in the following areas:

- Biotechnological intervention for conversion of MSW to energy.
- Biotechnological intervention for Conversion of MSW to biochemical.

BIRAC decided to focus initially on conversion of MSW to energy.

### c) mHealth

BIRAC in order to cater to the mHealth challenges commissioned a report to Cyber Media Research to understand the mHealth segment better in terms of technologies that it encompasses, the ecosystem it works in, the key stakeholders and initiatives currently ongoing.



BIRAC and Cyber Media Research consultative meets have assessed the mHealth Opportunities in India and prepared a document on the mHealth ecosystem, key technologies, key stakeholders, and enabled BIRAC to take strategic decisions on the mHealth space.

A series of consultative meetings were organized with stakeholders to understand the challenges and needs of the mHealth sector.

#### Key Highlights of the program:

- mHealth: Mobile applications for healthcare
- The IT Perspective: Navigation, Positioning and Telecommunications
- Robotics in Health
- mHealth Challenges – Interoperability
- mHealth in the Indian Context

## 10. MENTORSHIP AND CAPACITY BUILDING

### 10.1 IGNITE

BIRAC and Centre of Entrepreneurial Learning (CfEL) of Judge Business School, University of Cambridge



initiated a partnership that enables five BIRAC supported applicants to take part in CfEL's flagship intensive entrepreneurial boot-camp programme called "Ignite" which is aimed at providing academics (PhDs, post-docs and scientists) entrepreneurial



*Ignite 2013 Batch of Cambridge University*

opportunities to explore their innovative ideas and transform them into a business project. The first batch of 5 fellows comprising of BIG grantees and Stanford India Bio-design fellows went to Cambridge in July 2013. The overall experience has been described as a tremendous learning opportunity by the participants. The programme helped the participants to strengthen their business plan around the commercial pitch apart from the technological backbone.

## 10.2 BIRAC ROADSHOWS

BIRAC organized a "Roadshow and workshop for promotion of Bio-Science industries in Punjab" in association with Punjab State Council for Science & Technology (PSCST), Mohali Biotech Park and Indian School of Business (ISB), Mohali on March 5-6, 2014, to sensitize the Biotechnology industry, entrepreneurs, start-ups and academia on the key issues about the evolving biotechnology landscape in India especially on the funding scenario for biotech innovation and how



*BIRAC Roadshow at Chandigarh, Punjab*

BIRAC is fostering the innovation. This also involved a session on effective grant writing skills as well as a dedicated workshop on IP issues. The event was attended by about 92 participants comprising of researchers, scientists, and academicians, representatives of small, medium and large industry, start-ups and students (postgraduate & graduate students from life science disciplines).

## 11 OUTREACH

### 11.1 BIRAC PRESENCE AT BIOKOREA 2013

BIRAC participated in BioKorea 2013. BIRAC with ABLE and Korea Health Industry Development Institute (KHIDI) has given an opportunity to Academic Research Institutions like THSTI, C-CAMP, and SMEs like Criyagen, Aaranya to exhibit at BioKorea 2013 held between September 11 and 13, 2013 at Seoul, South Korea. BIRAC has financially supported the participating Institutions and SMEs for Booth Space and its accessories, posters, meetings and industrial tour. BioKorea 2013 Business Forum provided an opportunity to enter into business or technology partnership with leading bio companies in Korea and other parts of the world.



*Indian Industry Delegation at BioKorea 2013*

Participation at BioKorea gave visitors a glimpse of BIRAC. Such platform brings in more branding and potential academic-industry collaboration in discovery of new molecules and industrial research. It also opened up an opportunity for BIRAC to showcase its activities on the global platform in the areas where India holds huge potential which is unfortunately untapped yet.

### 11.2 BANGALORE INDIA BIO

BIRAC also registered its presence in the annual Biotechnology Summit – Bangalore INDIA BIO, during

10<sup>th</sup>-12<sup>th</sup> February 2014. Bangalore INDIA BIO is an annual event organized by Department of Science & Technology, Government of Karnataka, under the guidance of Vision Group of Biotechnology. Since 2001, Bangalore INDIA BIO has been instrumental in promoting the inherent strength of the Indian biotech industry to the outside world and is now acknowledged as the biggest and India's National event on Life Sciences. The event gave an opportunity to BIRAC to showcase its activities to the industry, academia and researchers from across India and abroad. The event was leveraged by BIRAC as a platform to enhance its outreach to the potential target audience in the biotechnology space.

### 11.3 BIO ASIA 2014

Bio Asia 2014 conclave was organized at Hyderabad from 17<sup>th</sup>-19<sup>th</sup> February 2014. The event witnessed the participation of around 1200 delegates from 51 nationalities. The international event was promoted by Federation of Asian Biotech Associations, Government of Andhra Pradesh and Pharmaceutical Export Promotion Council of India. The focus theme was - Innovations in Life Sciences and R&D. BIRAC participated in the event by organizing a focussed session on "Creating an Innovation Ecosystem – Role of Industry, Academia, Government, Investors and Service Providers, Science Parks and others". Moreover, BIRAC also put up a stall at the exhibition area to enhance the outreach and branding of BIRAC activities and initiatives.



*BIRAC at Bio Asia 2014, Hyderabad*

### 11.4 BIRACi3 – THE QUARTERLY NEWSLETTER OF BIRAC

During the BIRAC 2<sup>nd</sup> Foundation Day on 20<sup>th</sup> March 2014, the quarterly newsletter – BIRAC i3, was launched by Prof. K. VijayRaghavan, Secretary, DBT



*Newsletter release at BIRAC 2<sup>nd</sup> Foundation Day*

and Chairman, BIRAC. The first edition of the newsletter was based on the theme of Enabling Transformations in the biotechnology sector which comprised the views of an eminent scientist, such as Dr. M.K. Bhan, BIRAC's Innovators Meet, profiles of BIRAC supported innovators and strategic partnerships forged by BIRAC to enable the transformation of ideas to product stage.

## 12. INDUSTRY ACADEMIC INTERACTION

### 12.1 SECOND INNOVATORS MEET- SEPTEMBER 2013

BIRAC organized its second Innovators Meet on 23<sup>rd</sup>- 24<sup>th</sup> September, 2013 at the Heritage Village Resort, Manesar, Haryana. The theme of the Innovators Meet 2013 - Catalysing the Growth of an Innovation Driven Biotech Enterprise – focused on policy changes and pathways to drive the Indian bio-economy to reach the level of US \$ 100 billion by 2025. More than 200 stakeholders including policy makers, industry leaders, entrepreneurs and academic researchers attended the meet.

To mark the occasion, a compendium of BIRAC funded schemes and innovative projects titled "BIRAC Innovators: Creating an impact" was officially released. The two day long meet witnessed deliberations on several relevant issues that impinge upon the growth of the biotechnology enterprise. These included funding opportunities and institutional regulatory gaps that bio-tech entrepreneurs need to negotiate.



*Compendium Release at BIRAC Innovators Meet 2013*





Participants at BIRAC Innovators Meet 2013

Strategies to foster innovation through bio-enterprises were also a subject of discussion that specifically focused on the needs of start-ups and SMEs, they being the engines of bio-innovation. The meet concluded with several recommendations for fostering the innovation in the Indian bio-economy and creating an environment that is conducive for the commercialization of socially relevant and responsive innovations.

The flagship BIRAC Innovators Award was given to five best innovations by the industry who have delivered cutting edge innovative products. The criteria of selection included the level of innovation, scientific merit and risk factor attached to each of the projects. The awardees were –

- Agriculture Sector: Aristogene Biosciences Pvt. Ltd., Bangalore for the development of improved PCR Kits with internal control for shrimp viruses WSSV, YHV, TSV and IHNV
- Healthcare Sector: Tergene Biotech Pvt. Ltd., Secunderabad for the development of an indigenous India specific 15 valent pneumococcal conjugate vaccine
- Biomedical Devices, Implants and Diagnostics Sector: Vinvish Technologies Pvt. Ltd., Trivandrum for the development of an indigenous PDT Laser system
- Industrial Processes and Green Technology Sector: Thermax Ltd., Pune for the development of Anaerobic Membrane Bioreactor (AnMBR) for waste to energy solutions
- Industrial Processes and Green Technology Sector: Millenium Exports, Chennai for the development of pet animal food, fish leather and other marine biotechnology products from fish waste

The Innovators Meet also provided a platform for start-ups to pitch their ideas to the audience and display their

innovative projects in the poster session. Out of the fourteen pitches made, two were adjudged as the best pitches – Achira Labs, Bangalore for Microfluidics-based platform for multiplexed point-of-care immunoassays and Mr. Jayant S. Karve, Fellow, Stanford India Biodesign for Intraosseous Access Device.

While evaluating the business pitches, the Jury Panel considered the presentation clarity, value proposition, project concept, business plan, stage of product development and ability to address the Jury concerns about the project.

A poster presentation was also organised during the event which witnessed the participation of 24 posters. Three entries were adjudged as best posters:

- a) *Kaveri Seed Co. Ltd.* for development of biotic stress resistance rice through conjunct use of Bio and Hybrid technologies marker-assisted dissection of genetic basis of yield and improving yield potential under drought stress in Maize
- b) *Oriental Aquamarine* for design modification and commercialization of nitrifying bioreactor technology for the establishment of organic recirculation prawn seed production system (Phase II)
- c) *Praj Industries* for Lignocellulosic Biomass to Ethanol Technology: Simultaneous Saccharification and Fermentation

## 12.2 FOUNDATION DAY ON MARCH 20, 2014

BIRAC's Second Foundation Day on March 20, 2014 brought together nearly 300 scientists from industry and academia, public and private sector, policy makers and national and international organizations. The theme for the Foundation Day celebrations was "Promoting Partnerships – Innovation Research to



Lighting the lamp-Prof. Padmanaban, Senior Science and Innovation Adviser, BIRAC, Prof. K VijayRaghavan, Secretary, DBT & Chairman, BIRAC & Dr. Renu Swarup, MD, BIRAC





*Delegates at BIRAC 2<sup>nd</sup> Foundation Day*

Product Development”. Various stakeholders of BIRAC leveraged the Foundation Day platform to discuss the priorities for making India globally competitive in the biotech arena.

The event was attended by a large number of international agencies that support scientific R&D. This included Bill & Melinda Gates Foundation, the Wellcome Trust, Tekes, USAID and Grand Challenges Canada. Embassies of several countries were represented at the event by their senior science counselors.

The agenda for the Foundation day was set in a way so as to focus the lectures, plenaries and panel discussions on issues that are critical for forging industry-academia partnerships and cross-border linkages to foster and nurture the bio-innovation ecosystem in the country.

In addition to lectures and plenary sessions, several panel discussions on key issues facing biotech industry were set up to elicit views of the galaxy of specialists invited for the function.

The event also witnessed discussions and deliberations for making India a global bio-manufacturing hub, with special emphasis on biopharma, bioindustrial and bioproducts. Financing options in the biomanufacturing were also discussed.

The panel discussions led to spirited and intense discussions comprehensively reviewing the relevant issues in all their dimensions with enthusiastic participation of those in the audience as well. The event concluded with a lively discussion on steps that are needed for creation of a talent pool for the biotech sector as well as for retention of talent in that pool over the long run.

### 13. INTERNAL CONTROL SYSTEM AND THEIR ADEQUACY

The Company has established systems providing adequate internal controls, commensurate with its size and nature of the business. Such systems have been appropriately documented. There is very clear policy to maintain confidentiality and ensure No-Conflict of Interest.

### 14. HUMAN RESOURCES

The year 2013-14 has been a challenging year so far as human resource matters were concerned. While BIRAC has been able to develop a unique organisation structure, contract career development path and HR policy, recruitment of personnel to hold various responsible positions with a view to fulfilling the objectives was a very difficult task. It goes to the credit of the organisation that BIRAC has been able to hire 21 personnel from different disciplines and domain areas. All those recruited were in position by October 2013.

### TRAINING

During the year 2013-14, training of 40 man-days was given to the employees of BIRAC. A half day workshop run by Dr. Nandidesh Nilay, Director of Training Requirement and New Concepts (TraNc) on ‘Human Values’ was conducted on February 17, 2014 for 20 employees of BIRAC and the need based workforce.

A one day scientific writing and publishing workshop was organised by Macmillan Science Communication, JNU on November 29, 2013 wherein 20 employees participated. Besides, the employees were also given induction training on August 6-7, 2014. 18 employees participated in this training which was conducted for half day each on 6<sup>th</sup> and 7<sup>th</sup> August, 2013.



*Scientific writing and publishing workshop at JNU*

## BIRAC LIBRARY

BIRAC has a small library consisting of books, reports and journals. The requirement of library is however met by subscribing to approximately 727 journals of 19 publishers through DBT e-library consortium (DeLCON). This is a unique electronic consortium with 14 members since August 2013. The DeLCON subscription price of publishers is borne by member institutions proportionately. The journals are accessible through the DeLCON portal (<http://delcon.gov.in>) to the member institutions.

## 15. FUTURE OUTLOOK

### 15.1 TRANSLATIONAL FACILITIES FOR PRE-CLINICAL TOXICOLOGY AND PHASE I CLINICAL TRIALS

The process of new drug discovery and their full evaluation in patients incorporates five fundamental stages of preclinical, Phase I, Phase II, Phase III and Phase IV. Pre-clinical studies predict safety & efficacy in animal models and thus support conduct of research in humans. Similarly, Phase I studies give information on safety & tolerability in healthy volunteers and support moving to patients. Extrapolation of animals to patients through healthy volunteers plays a significant part in the drug discovery process and thus pre-clinical toxicology studies and Phase I clinical trials play an important role.

BIRAC recognized the need for national level pre-clinical toxicology and Phase I clinical trial facilities which can be accessed by start-ups, SMEs and public sector researchers for taking their research leads into the next stage of validation and trial.

BIRAC is presently focussing on setting up a pre-clinical toxicology facility by strengthening a private sector institution and make it accessible to researchers. The necessary ground work has already been completed.

### 15.2 MISSION FOR ACCELERATING DISCOVERY RESEARCH TO EARLY DEVELOPMENT OF BIOLOGICALS (NATIONAL BIOPHARMACEUTICAL ACCELERATOR PROGRAM)

Research on biologics and biopharmaceuticals has emerged as the focus area in the last few decades. The

current global efforts are focused on advancing biological and inter disciplinary science to accelerate the pace of biopharmaceutical R&D. There is a need to accelerate India's capabilities also in these areas so that India emerges as a hub for design and development of novel, affordable and effective biopharmaceutical products. BIRAC aims to provide the cutting edge skills of scientific leadership through industry-academia collaboration in this important research space with a national mission focussing on innovation and translational research for accelerating discovery research to early development. BIRAC presents itself as the foundational building block in the national mission on biologics and biopharmaceuticals.

BIRAC has already organized few stakeholder meetings and analysed the current 'art of the possible in India' to define the blue print and implement the mission. A Program Proposal Management Unit (PPMU) is also being created to assist conducting and coordinating the future activities.

### 15.3 RESEARCH ALLIANCE FOR PRODUCT INNOVATION AND DEVELOPMENT INITIATIVE (RAPID)

BIRAC launched RAPID focussing on accelerating rapid development of nationally important technologies and products that will need co-ordinated efforts from understanding national & market needs, policy & milieu surrounding a technology/product to technology acquisition and development, if need be.

#### *Wheat Project*

BIRAC aims to support a project on "Improved wheat for heat tolerance and climate resilience" which addresses a very crucial area of crop biotechnology under the RAPID initiative in collaboration with USAID. The goal of the proposed project is to develop high yielding heat tolerant wheat cultivars for the Indo-Gangetic plains.

BIRAC is presently exploring the possibilities of involving more Government funding agencies in this initiative and identified the major activities for taking this initiative forward i.e. setting up of centralized facilities for haploid production and genotyping, training of man on word power and the relevant wheat varieties.

**For and on behalf of Board**

Date: 9<sup>th</sup> September 2014  
Place : New Delhi

Prof. K VijayRaghavan  
Chairman

## ACCOMPLISHMENTS

### Products/Technologies/Process Developed through BIRAC funding

S.No	Company & Collaborator	Title of the proposal	Salient Features	Current Status
<b>Products</b>				
1.	Designinnova with ICGEB /DBT/Univ. of Turku	Design and development of an affordable fluorescence reader for point of care diagnostics	This technology will help to detect multiple infections simultaneously in remote settings and ensures less medical waste in blood banks. This can be adopted for inexpensive tests for detection of HIV, HCV, HBV, Syphilis and Tuberculosis infections	Ready for commercialization. One unit has already been sold
2.	Healthline Pvt. Ltd.	Developing face mask for cosmaceutical application using sericin and other natural bio active agent on non-woven silk sheet	'Fibro heal' was developed based on silk protein for burn wound management	This mask is in use at AIIMS.
3.	Janacare Solutions Pvt. Ltd., in collaboration with AIIMS, New Delhi and Narayana Hrudayalaya Hospital, Bangalore	DX Phone	'AINA' device developed & commercialized by Janacare was clinically validated and measures blood glucose, HbA1C, lipids (HDL, LDL, TrG), Creatinine and Haemoglobin. The device can be used in hospitals for in-patient management, for self-monitoring in patients and for screening by health workers.	Ready for commercialization. The Company has already got Pre orders for 25,000 units from India.
4.	Optra Systems Pvt. Ltd.	ONCOSCANNER – Digital Oncopathology slide Scanner	This will offer complete digital pathology solution with ease of operations, scalability, security and integration with software for image viewing and management at affordable costs.	Ready for validation in second phase
5.	Span Diagnostics Ltd.	Manufacturing and commercialization of a low cost and reliable clinical chemistry analyzer	Autochem Ingenious: This product will help early diagnosis thereby reducing the overall expenditure on healthcare. Robust design to withstand large power fluctuations	Ready for commercialization
6.	Vinvish Technologies Pvt. Ltd.	Design and Development of Photo Dynamic Therapy (PDT) Laser System	Indigenous and low cost PDT laser system for cancer treatment	Ready for clinical trials
<b>Technologies</b>				
1.	Persistent	A comprehensive Next Generation Sequence (NSG) data analysis solution	Application is in re-sequencing of human genomes to enhance understanding of genetic differences in health and diseases	Commercialized.
2.	Strand Life Sciences Pvt. Ltd.	Hepatotoxicity prediction platform	Capable of providing insights into drug induced liver injury and will help in replacing/reducing the use of animals and increase efficiency of drug development by predicting hepatotoxicity	Commercialized.
3.	Bharat Serums and Vaccines Ltd.	Process Development and scale up of a commercially viable manufacturing process of an essentially similar therapeutic peptide based implant with anti-cancer properties and development of a technology platform for implant based sustained release formulations incorporating therapeutic peptides/recombinant proteins	Development of indigenous drug delivery technology for implant of Goserelin, used for the treatment of breast and prostate cancer, to release the drug over an extended period of time	Ready for commercialization

S.No.	Company & Collaborator	Title of the proposal	Salient Features	Current Status
4.	Rossari Biotech	Viable Enzymes production using Agro waste/produce as raw material of Industrial/Feed and health care use with large viable Market/demand	Technology was developed for indigenous production of amylase and lipase enzymes at 1000 L scale.	Ready for production.
5.	Nagarjuna Fertilizers & Chemicals Ltd., (NFCL)	Transformational technology platform development for biological hydrogen	Biological hydrogen production is the vehicle to embark upon hydrogen economy and may also play a role for chemical industries in replacing their petroleum feedstock	Ready for pilot scale production. Scale-up version is envisaged to Handle between 50-100 MT raw Material/day
6.	India Glycols Ltd., with DBT-ICT Centre for Energy Biosciences/ICT, Mumbai	Setting up of 10 ton lignocellulosic biomass/day processing plant to produce about 3000 L ethanol/day	Setting up of decentralized commercial lignocellulosic ethanol plant is a requirement considering the need for ethanol free from vagaries of sugarcane production and with the availability of more than 250 million tonnes of surplus agricultural residue available in the country	Pilot plant for continuous production of 3000L/day is under construction
7.	Tata Chemicals Ltd., with Amrit Institute of Nanosciences/Rallis	Inorganic and polymer nano-composites for micronutrient & pesticide delivery: Boosting crop health and yield	Nanotechnology based delivery vehicles to supply micro-nutrients & pesticides to crops to boost crop health, quality and yield	Ready for field trials

**Process**

1.	Indo American Hybrid Seeds(India) Pvt. Ltd. Bangalore	Utilization of marker assisted selection for development of salt tolerant hybrids in rice (Oryza sativa) (Phase- I)	Stable saline tolerant cytoplasmic male sterile lines of rice were generated which can be used for production of hybrid seeds using saline tolerant restorer lines to increase rice production	Ready for field trials
2.	Abhay Cotex Pvt. Ltd.,	Single step extraction of cottonseed with miscella refining	This process produces better oil with enhanced recoveries. Alternate protein sources can be fed to animals so that soya bean meal will be available for humans	Product is in the market

**Early stage technologies**

S.No.	Company & Collaborator	Title of the proposal	Salient Features
1.	Anthem Biosciences Pvt. Ltd. with Mitra Biotech Pvt. Ltd.	PAT-1102: A novel HDAC inhibitor for cancer therapy	The present HDAC inhibitor is expected to offer safe and affordable therapy to cancer patients in India
2.	Crystalline Research Pvt. Ltd. with NIN, Hyderabad	Clinical trials of novel anticancer drug co-crystal	A hydrolytically stable formulation of Temozolomide that is relevant to tropical zone IV region countries e.g. India, South America
3.	Incozen Therapeutics Pvt. Ltd.	Discovery and development of potent, selective and novel c-Met kinase inhibitors in cancer	These inhibitors belong to tyrosine kinase inhibitors which represent targeted therapies having specific effect on cancerous cells rather than a mass effect on a tissue or organ
4.	Rasayani Biologics Pvt. Ltd.	Evaluation of platinum nano particles for the treatment of hormone refractory prostate cancer	Indigenous, cost effective and affordable Platinum based treatment for the management of malignancies
5.	Sericare, Division of Healthline Pvt. Ltd.	Silk protein blend film for wound management, standardization of production process, clinical evaluation, value enhancement and concept establishment	Useful for the healing of auto graft wounds and diabetic wounds

S.No.	Company & Collaborator	Title of the proposal	Salient Features
6.	Achira Labs Pvt. Ltd.	Development of an aptamer-based platform to detect novel Tuberculosis markers in human serum	Simple, affordable and accurate diagnostic testing for tuberculosis using the emerging aptamer technology
7.	Pandorum Technologies Pvt. Ltd.	Modular Resilin Mimetic Elastomeric Platform	Novel class of bio-inspired hydrogels with flexible properties offer smart delivery systems for various classes of lifesaving drugs and mechanically demanding tissue engineering scaffolds
8.	Stempeutics Research	A parallel group randomized open blinded end point evaluation, multicentre, dose escalation, Phase II study assessing the safety and efficacy of intra-arterial ex-vivo cultured adult allogenic mesenchymal stem cells in patients with alcoholic liver cirrhosis	Offers early and safe intervention to restore or salvage the normal functions of liver
9.	Thermax Ltd.	Development of Anaerobic Membrane Bioreactor (AnMBR) for waste to energy solution	Expected to create a major impact in developing countries by providing sustainable solutions towards energy demand and waste water management issues
10.	Nagarjuna Fertilizers & Chemicals Ltd.	Development of technology platform for rare sugar production Phase I	Rare sugars have been produced using immobilized recombinant enzymes expressed and purified from E.coli. The platform can use wide range of raw materials including cellulosic sugars
11.	Aumgene Biosciences	Cloning and expression of recombinant lipase enzyme (Phase 1)	Technology for Thermomyceslanuginosus (TL) Lipase production upto 100 L scale. The enzyme has applications in food industry, biodiesel production and fine chemicals
12.	Kaveri Seed Company Ltd.	Development of biotic stress resistant rice through conjunct use of bio and hybrid technologies	Contributes to productivity increase which in turn creates revenue pathways to farmers
13.	Geo Biotechnologies India Pvt. Ltd.	Association Mapping and Whole Genome Marker Assisted Recurrent Selection for Development of Abiotic and Biotic Stress Resilient Maize	The markers identified in the association mapping study of drought would give added value and accuracy in MARS for drought tolerance inbred development program
14.	Bio Seed Research India Pvt. Ltd.	Identification of QTL(s) for drought tolerance and their introgression in elite cultivars of rice	Validated QTL (s) will aid in our understanding of the genetics of drought tolerance and development of more drought tolerant cultivars
15.	Ankur Seeds Pvt. Ltd., with ICGEB	Third generation RNAi for engineering Tomato Leaf Curl (ToLCV) and Tospovirus (GBNV) resistance in tomato	Beneficial for the society by improving the yield through Tomato Leaf Curl and Tospo virus resistance hybrids
16.	Sri Biotech Laboratories India Ltd., with Univ. of Delhi	Control of shoot and fruit borer insect pest (Leucinodesorbonalis) in brinjal through RNA interference	Insect resistant brinjal without fruit damage is preferred for human consumption and the farmer's community will benefit economically. The pesticide residues on the harvest are expected to reduce heavily



**Intellectual Property**

S.No	Company Name	Patent Application No.	Title	Features
<b>IP Generated</b>				
1	C-CAMP	PCT/IB2013/050871	Microfluidic flow analyzer for pathological detection and method thereof	Technology for inexpensive tests for detection of HIV, HCV, HBV, Syphilis and Tuberculosis infections.
2	Perfint Pvt Ltd	IN458/CHE/2013	Electronic docking system and method for robotic positioning system	The integrated planning navigation and training platform for tumor ablation
3	Incozen Therapeutics Pvt Ltd	PCT/IB2013/051577	Novel 3,5-disubstitued-3h-imidazo[4,5-b]pyridine and 3,5- di-substitued-3h-[1,2,3]triazolo[4,5-b] pyridine compounds as modulators of c-met protein kinases	First-in-class Kinase inhibitors for the treatment of cancer
4	Codon Biotech Private Limited	IN2671/DEL/2013	A novel process for production of 1,3, propanediol from biodiesel waste glycerol by mutant Enterobactoraerogenes and its cost effective purification	Novel process for the production of 1,3-propanediol from biodiesel waste glycerol
<b>IP Facilitated</b>				
1.	Pelican Biotech and Chemicals Labs Pvt. Ltd	IN414/CHE/2013	Novel chitin/ demineralised dehydrated chitinaceous / crustacean exoskeleton - based formulation containing microbes that generate chitinase/ protease enzymes	Novel formulation for the generation of enzymes
2.	Sea-Gull Limited	IN2050/MUMNP/2013	A simple two plasmid mammalian expression system for production of recombinant proteins and viruses	Novel and simple expression system for the production of recombinant proteins and viruses



## COMPLIANCE CERTIFICATE U/S 383A(1) OF THE COMPANIES ACT READ WITH COMPANIES (COMPLIANCE CERTIFICATE) RULES, 2001

Company Identification No. : U73100DL2012NPL233152  
Registration No. of the Company : 233152  
Nominal Capital : Rs. 1,00,00,000  
(Rupees One Crore Only)

To,

The Members

Biotechnology Industry Research Assistance Council

A-254, Bhisham Pitamah Marg,

Defence Colony,

New Delhi 110024

Sir(s),

We have examined the registers, records, books and papers of 'Biotechnology Industry Research Assistance Council (the Company)' as required to be maintained under the Companies Act, 1956 (the Act) and the rules made thereunder and also the provisions contained in the Memorandum and Articles of Association of the Company for the period ended on 31<sup>st</sup> March, 2014. In our opinion and to the best of our information and according to the examinations carried out by us and explanations furnished to us by the Company, its officers and agents, we certify that in respect of the aforesaid financial year:

1. The Company has kept and maintained all statutory registers as stated in Annexure 'A' to this report, as per the provisions of the Act, and the rules made thereunder and all entries therein have been duly recorded.
2. The Company has duly filed the forms and returns as stated in Annexure 'B' to this report with the Registrar of Companies as prescribed under the Act and the rules made there under.
3. The Company being private limited Company under Section 25 of the Companies Act, 1956 has the minimum prescribed paid-up capital and its maximum number of members during the said financial year were three excluding its present and past employees and the Company during the year under scrutiny:
  - (i) has not invited public to subscribe for its shares or debentures; and
  - (ii) has not invited or accepted any deposits from persons other than its members, directors or their relatives.
4. The Board of Directors met four times respectively on 25<sup>th</sup> June, 2013, 11<sup>th</sup> September, 2013, 17<sup>th</sup> December, 2013 and 05<sup>th</sup> February, 2014, in respect of which meetings proper notices were given and the proceedings were properly recorded and signed in the Minutes Book maintained for the purpose.
5. The Company has not closed its Register of Members during the Financial Year.
6. The first Annual General Meeting for the financial year ended on 31<sup>st</sup> March, 2013 was held on 30<sup>th</sup> September, 2013 after giving due notice to the members of the Company and the resolutions passed thereat were duly recorded in Minutes Book maintained for the purpose.

7. No Extra Ordinary General Meeting was held during the financial year.
8. The Company being a Private Limited Company, Section 295 of the Act is not applicable.
9. The Company has not entered into any contracts falling within the purview of Section 297 of the Act.
10. The Company has made necessary entries in the register maintained under Section 301 of the Act.
11. The Company was not required to obtain any approvals from the Board of directors, members or Central Government u/s 314 of the Companies Act, 1956.
12. The Company has not issued any Duplicate Share Certificate during the Financial Year.
13. The Company has:
  - a. delivered all the certificates on lodgement thereof for transfer in accordance with the provisions of the Act. There was no allotment/transmission of securities during the financial year;
  - b. has not deposited any amount in a separate Bank Account as no dividend was declared during the financial year.
  - c. was not required to post warrants to any member of the Company as no dividend was declared during the financial year.
  - d. has duly complied with the requirement of Section 217 of the Act.
  - e. was not required to transfer any amount to Investor Education & Protection Fund as there did not exist any amounts in unpaid dividend account, application money due for refund, matured deposits, matured debentures and the interest accrued thereon which have remained unclaimed or unpaid for a period of seven years.
14. The Board of directors of the Company is duly constituted and the appointment of additional directors, alternate directors and directors to fill casual vacancy have been duly made during the financial year.
15. The Company being private company provisions of Section 269 of the Act with regard to appointment of Managing Director/Whole Time Director/Manager are not applicable.
16. The Company has not appointed any sole-selling agents during the financial year.
17. The Company was not required to obtain any approvals of the Central Government, Company Law Board, Regional Director, Registrar and/or such other authorities as prescribed under the various provisions of the Act during the year.
18. The directors have disclosed their interest in other firms/ companies to the Board of Directors pursuant to the provisions of the Act and the rules made thereunder.
19. The Company has not issued any securities during the financial year.
20. The Company has not bought back any shares during the financial year.
21. There was no redemption of preference shares or debentures during the financial year.
22. There were no transactions necessitating the Company to keep in abeyance the rights to dividend, rights shares and bonus shares pending registration of transfer of shares.
23. The Company has not invited/ accepted any deposits including any unsecured loans falling within the purview of Section 58A during the financial year.
24. The Company, being a private Company, the borrowings made during the financial year do not attract provisions of Section 293(1)(d) of the Act.
25. The Company has not made any loans or advances or given guarantees or provided securities to other bodies corporate and consequently no entries have been made in the register kept for the purpose.
26. The Company has not altered the provisions of the Memorandum with respect to situation of the Company's registered office from one State to another during the year under scrutiny.

27. The Company has not altered the provisions of the Memorandum with respect to the objects of the Company during the year under scrutiny.
28. The Company has not altered the provisions of the Memorandum with respect to name of the Company during the year under scrutiny.
29. The Company has not altered the provisions of the Memorandum with respect to share capital of the Company during the year under scrutiny.
30. The Company has not altered its Articles of Association during the year under scrutiny.
31. There was no prosecution initiated against or show cause notices received by the Company and no fines or penalties or any other punishment imposed on the Company during the financial year.
32. The Company has not received any money as security from its employees during the financial year.

For Neelam Gupta & Associates  
Company Secretaries

Sd/-

(Neelam Gupta)

Proprietor

C. P .No. 6950

**Date: 5<sup>th</sup> September 2014**

**Place : New Delhi,**

## ANNEXURE A

Registers as maintained by the Company:

Sl. No.	Under section	Description	Comments
1.	150, 151	Register of Members/ Index of Members	Maintained
2.	163	Registers and Returns	Maintained
3.	--	Minutes Book of Meetings	Maintained
4.	303	Register of Directors, Managing Director, Manager and Secretary	Maintained
5.	307	Register of Directors' Shareholdings	Maintained
6.	Regulation 71 of Table A	Register of Directors' Attendance	Maintained
7.	--	Register of Shareholders' Attendance	Maintained
8.	--	Register of Transfer	Maintained
9.	209	Books of Accounts	Maintained
10.	Rule 7 of the Companies (Issue of Share Certificates) Rules, 1960	Register of Renewed and Duplicate Certificates	Maintained
11.	301	Register of Particulars of Contracts in which Directors are Interested	Maintained
12.	—	Register of Fixed Assets	Maintained

## ANNEXURE B

Forms and Returns as filed by the Company with Registrar of Companies during the financial year ending 31<sup>st</sup> March, 2014.

Sl. No.	Form No./Return	Filed under Section	Brief description of Document(s)/ Form(s)/ Return(s)	Date of filing
1.	Form 20B	159(1)	Annual Return	25.11.2013
2.	Form 23AC & ACA	220	Balance Sheet	08.11.2013
3.	Form 66	383A	Compliance certificate	22.11.2013
4.	Form 32	303	Particulars of Appointment of Directors, and Changes Made	15.01.2014
5.	Form 32	303	Particulars of Appointment of Directors, and Changes Made	19.08.2013
6.	Form 32	303	Particulars of Appointment of Directors, and Changes Made	07.06.2013
7.	Form 32	303	Particulars of Appointment of Directors, and Changes Made	07.06.2013
8.	Form 32	303	Particulars of Appointment of Directors, and Changes Made	06.06.2013
9.	Form 32	303	Particulars of Appointment of Directors, and Changes Made	06.06.2014
10.	Form 2	75	Return of allotment	08.01.2014

For **Neelam Gupta & Associates**  
Company Secretaries

Sd./-  
**(Neelam Gupta)**  
Proprietor  
C. P .No. 6950

Date: 5<sup>th</sup> September 2014  
Place : New Delhi

# Report on Corporate Governance



## REPORT ON CORPORATE GOVERNANCE

### 1. BIRAC PHILOSOPHY ON GUIDELINES ON CORPORATE GOVERNANCE

Corporate governance refers to the set of systems, principles and processes by which a company is governed. They provide the guidelines as to how the company can be directed or controlled such that it can fulfill its goals and objectives in a manner that adds to the value of the company and is also beneficial for all stakeholders in the long term. Stakeholders in this case would include everyone ranging from the board of directors, management, shareholders to customers, employees and society. BIRAC is committed to sound principles of Corporate Governance with respect to all its policies, practices and procedures. The Company's policy clearly reflects its values of transparency, professionalism and accountability. BIRAC constantly strives to uphold these values so as to generate long term economic value to all the stakeholders

### 2. BOARD OF DIRECTORS

The Board of Directors consists of seven directors viz. an executive Chairman, an executive Managing Director, 4 independent directors and 1 Government Nominee director

Four board meetings of the Company were held on the following dates: June 25, 2013, September 13, 2013, December 17, 2013 and February 5, 2014

The details of directors and board meetings attended are as follows:

Name of the director	Category	Directorships in other companies	Member / Chairman of Committees in other companies		Board Meetings attended (Nos.)	Attendance at last AGM	Remarks
			Member	Chairman			
<b>Prof. K. VijayRaghavan</b>	Chairman (Executive)	3	NIL	NIL	4	Yes	
<b>Dr. Renu Swarup</b>	Managing Director (Executive)	1	NIL	NIL	4	Yes	
<b>Prof. Ashok Jhunjhunwala</b>	Independent Director	12	4	1	3	NA	Tenure from 25.06.2013
<b>Prof. Deepak Pental</b>	Independent Director	NIL	NIL	NIL	2	NA	Tenure from 25.06.2013
<b>Dr. Dinakar Masanu Salunke</b>	Independent Director	NIL	NIL	NIL	3	NA	Tenure from 25.06.2013
<b>Dr. Gagandeep Kang</b>	Independent Director	NIL	NIL	NIL	3	NA	Tenure from 25.06.2013
<b>Dr. Mohd. Aslam</b>	Government Nominee	NIL	NIL	NIL	1	NA	Tenure from 17.12.2013



None of the Directors on the Board hold directorship in more than 15 companies as prescribed under the Companies Act, 1956. None of the Directors are members of more than 10 committees and or act as Chairman of more than 5 committees as prescribed under the Guidelines on Corporate Governance for Central Public Sector Enterprises (CPSEs) issued by the Department of Public Enterprises (DPE)

There are no pecuniary relationships or transactions of the non-executive directors of the Company.

### 3. AUDIT COMMITTEE

BIRAC is registered under Section 25 of the Companies Act, 1956 as a not for profit company. It is a private limited company which is not listed on any stock exchange. The constitution of audit committee is not applicable to the company as it is not a public listed company. However, constitution of an Audit Committee is a requirement of the DPE Guidelines on Corporate Governance. Accordingly, an Audit committee of the Board was constituted with 3 directors, Prof. Ashok Jhunjhunwala, Dr. Dinakar Masanu Salunke who were independent and Dr. Renu Swarup, who is the executive Managing Director of BIRAC on 1<sup>st</sup> May, 2014. Dr. Dinakar Masanu Salunke was appointed as the Chairman of the Committee. The terms of reference of the Committee are as follows:

1. Oversight of the company's financial reporting process and the disclosure of its financial information to ensure that the financial statement is correct, sufficient and credible.
2. Recommending to the Board, the appointment, re-appointment and, if required, the replacement or removal of the Internal auditor and the fixation of audit fees.
3. Recommending to the Board, for fixation of audit fees of the Statutory Auditors appointed by C&AG and approval of payment to statutory auditors for any other services rendered by them.
4. Reviewing, with the management, the annual financial statements before submission to the board for approval, with particular reference to:
  - a. Matters required to be included in the Director's Responsibility Statement to be included in the Board's report in terms of clause (2AA) of Section 217 of the Companies Act, 1956
  - b. Changes, if any, in accounting policies and practices and reasons for the same
  - c. Major accounting entries involving estimates based on the exercise of judgment by management
  - d. Significant adjustments made in the financial statements arising out of audit findings
  - e. Compliance with listing and other legal requirements relating to financial statements
  - f. Disclosure of any related party transactions
  - g. Qualifications in the draft audit report.
5. Reviewing, with the management, the half yearly financial statements before submission to the board for approval
- 5A. Reviewing, with the management, the statement of uses/application of funds raised through DBT and the report submitted by the monitoring agency monitoring the utilisation of proceeds and making appropriate recommendations to the Board to take up steps in this matter.
6. Reviewing, with the management, performance of statutory and internal auditors, and adequacy of the internal control systems.
7. Discussion with the internal auditors regarding any significant findings and follow up there on.
8. Reviewing the findings of any internal investigations by the internal auditors into matters where there is suspected fraud or irregularity or a failure of internal control systems of a material nature and reporting the matter to the board.
9. Discussion with statutory auditors before the audit commences, about the nature and scope of audit as well as post-audit discussion to ascertain any area of concern.

10. To look into the reasons for substantial defaults in the payment towards the statutory liabilities.
11. Carrying out any other function as is mentioned in the terms of reference of the Audit Committee.

#### 4. BOARD PROCEDURE

The meeting of the board of directors are generally held at the Company's registered office in New Delhi. The Company complies with the statutory requirements for holding board meetings. Apart from the statutory matters requiring the Board's approval, all major decisions including financial results, actual operations, feedback reports and minutes of meetings are regularly placed before the Board.

#### 5. SHAREHOLDER INFORMATION AS ON 31<sup>st</sup> March 2014

Category Code	Category of shareholders	Total no. of shares	Total value of shares (in Rs.)	Total Shareholding as a percentage of total number of shares
Shareholding of Promoter and Promoter Category	President of India	9000	90,00,000	100
	Prof. K. VijayRaghavan (held on behalf of President of India)	900	9,00,000	
	Dr. Renu Swarup (held on behalf of President of India)	100	1,00,000	
<b>GRAND TOTAL</b>		10000	1,00,00,000	100

#### 6. GENERAL BODY MEETINGS

The details of the Annual General Meetings are as follows:

Period ended on	Venue	Date	Time
31 <sup>st</sup> March 2013	A-254, 3 <sup>rd</sup> floor, Bhisham Pitamah Marg, Defence Colony, New Delhi - 110024	30 <sup>th</sup> September 2013	11.30 a.m.
31 <sup>st</sup> March 2014	1 <sup>st</sup> floor, MTNL Building, 9, CGO Complex, Lodhi Road, New Delhi-110003	30 <sup>th</sup> September 2014	10.00 a.m.

No special resolutions had been passed at the last Annual General Meeting.

#### 7. DISCLOSURES

1. Company has not entered into any material, financial or commercial transaction with the Directors or the management or their relatives in which they are either directly or through their relatives interested as directors and/or partners
2. The Company has complied with applicable rules and regulations and no penalties or strictures were imposed on the Company by any statutory authority during the last two years.
3. The Department of Public Enterprises, Ministry of Heavy Industries & Public Enterprises, Govt. of India vide its OM dated 14.05.2010 issued revised guidelines on Corporate Governance for CPSEs. As per

the guidelines, the provisions of the Corporate Governance are mandatory for all CPSEs including Section 25 companies. The Board of Directors of the company have adopted the guidelines during the year 2013-14 and it has complied with the applicable provisions of the guidelines of Corporate Governance.

4. Department of Public Enterprises vide its OM dated 29.07.2010 advised all CPSEs to submit an annual compliance report on implementation of policies and guidelines issues by DPE by 30<sup>th</sup> June every year. In compliance to directives of DPE, BIRAC submitted its Compliance Report to Department of Biotechnology for onward transmission to DPE.
5. No item of expenditure was debited in the Books of Accounts which was not for the purpose of the organization.
6. No expenses of personal nature of the Members of the Board of Directors were incurred out of the funds of the Company.

## **8. MEANS OF COMMUNICATION**

Members/Shareholders are apprised about the performance of the Company at each Annual General Meeting. The Company is an unlisted, private Section 25 company (now a Section 8 Company under the Companies Act, 2013) and therefore, the need to communicate its quarterly or half-yearly results does not arise.

## **9. MEMORANDUM OF UNDERSTANDING WITH THE DEPARTMENT OF PUBLIC ENTERPRISES**

The first MOU performance was rated "Excellent" receiving a score of 94% for CPSE grading on basis of Compliance with Guidelines on Corporate Governance for Central Public Sector Enterprises (CPSE) for the FY 2012-13 by the Department of Public Enterprises.

## **10. COMPLIANCE CERTIFICATE**

In terms of Clause 8.2 of DPE guidelines on Corporate Governance, a Certificate from a Practising Company Secretary, M/s. Neelam Gupta & Associates, New Delhi confirming the Compliance with the provisions of Corporate Governance forms a part of the report on Corporate Governance.

## **11. CODE OF CONDUCT**

BIRAC is committed to conduct business in accordance with the highest standards of business ethics and compliance with the applicable laws, rules and regulations. A Code of Business Conduct & Ethics in accordance with the DPE Guidelines has been laid down for all the Board members and senior management.

All the members of the Board and senior management personnel have affirmed compliance with the same for the financial year 2013-14. The Code of Business Conduct & Ethics has also been put up on the website of the Company ([www.birac.nic.in](http://www.birac.nic.in))

## **DECLARATION AS REQUIRED UNDER THE DPE GUIDELINES ON CORPORATE GOVERNANCE**

"All the members of the Board and Senior Management Personnel have affirmed compliance of the Code of Business Conduct & Ethics for Board Members and Senior Management for the financial year ended on March 31, 2014"

Sd/-  
**Dr. Renu Swarup**  
Managing Director

## CERTIFICATE OF COMPLIANCE OF CORPORATE GOVERNANCE AS PER THE GUIDELINES OF DEPARTMENT OF PUBLIC ENTERPRISES (DPE) BY A COMPANY SECRETARY IN WHOLE TIME PRACTICE.

### To the members of Biotechnology Industry Research Assistance Council (BIRAC)

We have examined the compliance of the conditions of Corporate Governance by Biotechnology Industry Research Assistance Council ("the Company") for the year ended on March 31, 2014, as stipulated in the guidelines of Corporate Governance for Central Public Sector Enterprises (CPSEs) issued by Department of Public Enterprises (DPE) vide its order dated May 14, 2010.

The compliance of the conditions of Corporate Governance is the responsibility of the Management. Our examination was carried out in accordance with the provisions of the guidelines of DPE and limited to a review of the procedures and implementation thereof, adopted by the Company, for ensuring the compliance of the conditions of Corporate Governance. It is neither an audit nor an expression of opinion of the financial statement of the Corporation.

In our opinion and to the best of our information and according to the explanations given to us, and according to the records and documents maintained by the Company, we certify that the Company has complied with the conditions of Corporate Governance, as stipulated in the guidelines of DPE.

We further state that such compliance is neither an assurance as to the future viability of the Company nor the efficiency or effectiveness with which the management has conducted the affairs of the Company.

For Neelam Gupta & Associates  
Company Secretaries

Sd/-  
**(Neelam Gupta)**

Practicing Company Secretary  
Proprietor  
PCS 6950

Date: 5<sup>th</sup> September 2014  
Place: New Delhi

# Auditors' Report & Annual Accounts





## **SAMPRK & ASSOCIATES CHARTERED ACCOUNTANTS**

### **INDEPENDENT AUDITOR'S REPORT**

To The Members of  
**BIOTECHNOLOGY INDUSTRY RESEARCH ASSISTANCE COUNCIL**

#### **Report on the Financial Statements**

We have audited the accompanying financial statements of BIOTECHNOLOGY INDUSTRY RESEARCH ASSISTANCE COUNCIL, which comprise the Balance Sheet as at March 31, 2014, and the Statement of Income and Expenditure (from 1<sup>st</sup> April, 2013 to 31<sup>st</sup> March, 2014) for the year ended, and a summary of significant accounting policies and other explanatory information. We have issued this report in suppression of our report dated 16<sup>th</sup> July, 2014 consequent upon the revision of Balance Sheet, Income & Expenditure account of the Company in terms of observation of the Government Audit (C&AG of India) regarding certain changes as suggested in their Audit Notes.

#### **Management's Responsibility for the Financial Statements**

Management is responsible for the preparation of these financial statements that give a true and fair view of the financial position, financial performance of the Company in accordance with the Accounting Standards referred to in Sub-Section (3C) of Section 211 of the Companies Act, 1956 ("the Act"). This responsibility includes the design, implementation and maintenance of internal control relevant to the preparation and presentation of the financial statements that give a true and fair view and are free from material misstatement, whether due to fraud or error.

#### **Auditor's Responsibility**

Our responsibility is to express an opinion on these financial statements based on our audit. We conducted our audit in accordance with the Standards on Auditing issued by the Institute of Chartered Accountants of India. Those Standards require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether the financial statements are free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the financial statements. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the Company's preparation and fair presentation of the financial statements in order to design audit procedures that are appropriate in the circumstances. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of the accounting estimates made by management, as well as evaluating the overall presentation of the financial statements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

## Opinion

In our opinion and to the best of our information and according to the explanations given to us, the financial statements give the information required by the Act in the manner so required and give a true and fair view in conformity with the accounting principles generally accepted in India:

- a) In the case of Balance Sheet, of the state of affairs of the company as at 31<sup>st</sup> March, 2014
- b) In the case of Income and Expenditure , of the excess of income on expenditure for the year ended on that date; and

### Report on Other Legal and Regulatory Requirements

1. As required by the Companies (Auditor's Report) Order, 2003 ("the Order") issued by the Central Government of India in terms of sub-section (4A) of section 227 of the Act, we give in the Annexure a statement on the matters specified in paragraphs 4 and 5 of the Order. N/A
2. As required by section 227(3) of the Act, we report that:
  - a) we have obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purpose of our audit;
  - b) in our opinion proper books of account as required by law have been kept by the Company so far as appears from our examination of those books;
  - c) the Balance Sheet, and Statement of Income and Expenditure dealt with by this Report are in agreement with the books of account
  - d) in our opinion, the Balance Sheet, and Statement of Income and Expenditure comply with the Accounting Standards referred to in subsection (3C) of section 211 of the Companies Act, 1956;
  - e) In terms of Department of Company Affairs Notification No. GSR 829(E), dated 21<sup>st</sup> October, 2003 Government of Companies are exempt from applicability of provisions of section 274(1) (g) of the Companies Act, 1956.

Sd/-

For **S A M P R K & ASSOCIATES**  
Chartered Accountants  
Firm Registration No.-013022N

**CA. Pankaj Sharma**

(Partner)

Membership No. 093446

Place: New Delhi

Dated: 12<sup>th</sup> August 2014

Office:-102-03/106/302, Neelkanth House, S-524, School Block, Shakarpur, Delhi-110092

Phone: 011-22481918, 22482446, Mobile: 9810955575, 9212343336

Email: sharmapanjul@gmail.com/sharmapanjul@rediffmail.com

Adm Office: 302, Neelkanth House, S-524, School Block, Shakarpur, Delhi - 110092

## BALANCE SHEET

### Biotechnology Industry Research Assistance Council (BIRAC)

Balance Sheet As at 31st March, 2014

(Amount in Rs.)

	Particulars	Note No.	Figures as at the end of the current reporting period (31.03.2014)	Figures as at the end of the previous reporting period (31.03.2013)
<b>I</b>	<b>EQUITY AND LIABILITIES</b>			
(1)	Shareholder's Funds			
	(a) Share Capital	1	1,00,00,000	1,00,00,000
	(b) Reserves and Surplus	2	2,55,37,78,458	52,04,113
	<b>CURRENT LIABILITIES</b>			
	(a) Other Current Liabilities	3	27,16,03,433	37,72,49,979
	(b) Short Term Provisions	4	-	2,78,465
	<b>TOTAL</b>		<b>2,83,53,81,891</b>	<b>39,27,32,557</b>
<b>II</b>	<b>ASSETS</b>			
	<b>(1) Non-Current Assets</b>			
	<b>(a) Fixed Assets</b>			
	Tangible Assets	5	40,15,442	36,05,876
	Intangible Assets		3,96,690	5,38,390
	<b>(b) Long-Term Loans and Advances</b>	6	1,99,96,98,736	18,20,000
	<b>(2) Current Assets</b>			
	(a) Cash and Cash Equivalents	7	26,27,48,934	27,16,55,533
	(b) Other Current Assets	8	56,85,22,089	11,51,12,758
	<b>TOTAL</b>		<b>2,83,53,81,891</b>	<b>39,27,32,557</b>
Significant Accounting Policies and Notes to Accounts		Note no.14 & 15		

Notes from 1 to 15 are an integral part of Financial Statements

Sd/-  
Kavita Anandani  
(Company Secretary)

For and on behalf of Board of Directors of BIRAC  
Sd/-  
Renu Swarup  
(Managing Director)  
DIN No.01264943

Sd/-  
K.Vijay Raghavan  
(Chairman)  
DIN No.02721859

#### Auditors Report

As per our report of even date attached  
For SAMPRAK & Associates  
Chartered Accountants  
Firm Reg. No. 013022N

Sd/-  
CA. Pankaj Sharma  
(Partner)  
Membership No. 093446

Place : New Delhi  
Date : 12<sup>th</sup> August 2014

# INCOME & EXPENDITURE ACCOUNT

## Biotechnology Industry Research Assistance Council (BIRAC)

Statement of Income & Expenditure For The Period Ended 31st March, 2014

(Amount in Rs.)

	Note No.	Figures as at the end of the current reporting period (31.03.2014)	Figures as at the end of the previous reporting period (31.03.2013)
<b>(1) INCOME :</b>			
(a) Grants Received & Utilized	9	61,76,67,081	4,63,30,771
(b) Other Income	10	88,33,798	16,15,217
<b>Total Revenue</b>	<b>(A)</b>	<b>62,65,00,879</b>	<b>4,79,45,988</b>
<b>(2) EXPENDITURE:</b>			
(a) Programatic Activities	11	49,88,93,042	24,58,973
(b) Employee Benefit Expenses	12	2,20,69,034	53,44,991
(c) Depreciation & Amortisation Expenses	5	10,17,870	1,93,730
(d) Other Expenses	13	9,67,05,006	3,88,03,682
<b>Total Expenses</b>	<b>(B)</b>	<b>61,86,84,952</b>	<b>4,68,01,376</b>
<b>(3) Surplus of Income over Expenditure before prior period adjustments and tax C = (A-B)</b>		<b>78,15,927</b>	<b>11,44,612</b>
(4) Add Prior Period Income (net) (D)		31,87,314	-
(5) Surplus after prior period and before tax for the year (E = 3 - 4)		<b>1,10,03,241</b>	<b>11,44,612</b>
(6) Extraordinary Items (F = 5 - 6)		-	-
(7) Income Before Tax (G = 6 - 7)		<b>1,10,03,241</b>	<b>11,44,612</b>
Less: Provision for Income Tax		-	2,78,465
<b>Surplus for the Year Carried Forward to Reserve &amp; Surplus</b>		<b>1,10,03,241</b>	<b>8,66,147</b>
(8) Earning per equity share:			
(1) Basic		1,100.32	86.61
(2) Diluted		1,100.32	86.61
Significant Accounting Policies and Notes to Accounts	Note No.14 & 15		

Notes from 1 to 15 are an integral part of Financial Statements

### Auditors Report

As per our report of even date attached  
For **S A M P R K & Associates**  
Chartered Accountants  
Firm Reg. No. 013022N

Sd/-

**CA. Pankaj Sharma**

(Partner)

Membership No. 093446

Place : New Delhi

Date : 12<sup>th</sup> August 2014

Sd/-

**Kavita Anandani**

(Company Secretary)

For and on behalf of Board of Directors of BIRAC

Sd/-

**Renu Swarup**

(Managing Director)

DIN No.01264943

Sd/-

**K.Vijay Raghavan**

(Chairman)

DIN No.02721859

## Biotechnology Industry Research Assistance Council (BIRAC)

### Notes to Financial Statements

(Amount in Rs.)

1 Share Capital		
Particulars	Figures as at the end of the current reporting period (31.03.2014)	Figures as at the end of the previous reporting period (31.03.2013)
<b>A. Authorized</b> 10,000 (10,000) Equity shares of Rs 1000/- each	1,00,00,000	1,00,00,000
<b>B. Issued, Subscribed &amp; Fully paid</b> 10,000 (10,000) Equity shares of Rs 1000/- each fully paid up Subscribed but not fully paid	1,00,00,000 -	1,00,00,000 -
<b>TOTAL</b>	<b>1,00,00,000</b>	<b>1,00,00,000</b>

#### C. Reconciliation of Number of Shares

Particulars	Figures as at the end of the current reporting period (31.03.2014)	Figures as at the end of the current reporting period (31.03.2013)
	<b>No of shares</b>	<b>No of shares</b>
Number of equity shares at the beginning	10,000	-
Add: Equity shares issued during the year	-	10,000
Number of equity shares at the end (closing balance)	10,000	10,000

#### D. Details of Shareholder's holding more than 5% in equity shares of the company

Name of Shareholder	No. of fully paid up shares	% of shares held	Figures as at the end of the current reporting period (31.03.2014)	Figures as at the end of the previous reporting period (31.03.2013)
President of India	9,000	90.00	9,000	9,000
Dr. (Prof.) K VijayRaghavan (held on behalf of President of India)	900	9.00	900	900
Dr. Renu Swarup (held on behalf of President of India)	100	1.00	100	100
<b>TOTAL</b>	<b>10,000</b>	<b>100.00</b>	<b>10,000</b>	<b>10,000</b>

#### E. Other details and rights,

- The Company has only one class of equity shares issued at par value of Rs.1000 each.
- Each Equity shareholder has right to one vote per share.
- The shares do not have dividend rights.
- Shares carry no distribution right in the event of liquidation.



## 2. Reserves and Surplus

(Amount in Rs.)

Particulars	Figures as at the end of the current reporting period (31.03.2014)	Figures as at the end of the previous reporting period (31.03.2013)
<b>Capital Reserve</b> BIRAC Fund (Non Recurring) (This stands for utilisation of amount for purchase of fixed assets)	55,08,846	43,37,966
<b>Special Reserve</b> Portfolio Reserve - DBT (This stands for the DBT portfolio taken over by BIRAC as on 31/03/2014 which consists of the amount of loan granted by BCIL and interest accrued thereon as per Board approval dated 17th December, 2013)	2,50,25,74,146	-
Portfolio Reserve - DBT/Realised (This stands for the amount realised by BIRAC on behalf of DBT as per the Board approval w.e.f. 17th December, 2013)	3,38,26,078	-
<b>General Reserve</b>		
<b>Surplus</b>		
Opening Balance	8,66,147	-
Add: Transfer from Statement of Income & Expenditure	1,10,03,241	8,66,147
<b>TOTAL</b>	<b>2,55,37,78,458</b>	<b>52,04,113</b>

## 3. Current Liabilities

(Amount in Rs.)

Other Current Liabilities	Figures as at the end of the current reporting period (31.03.2014)	Figures as at the end of the previous reporting period (31.03.2013)
<b>Unutilised grant+ (Welcome Trust)</b>	10,99,33,492	10,32,97,534
<b>Unutilised grant (DBT-BMGF PMU)</b>	1,12,97,260	-
<b>Unutilised Grants Carried forward</b>		
BIRAC Fund ( I&M ) Sector	11,08,09,529	14,89,68,800
BIRAC Fund( Manpower)	-	46,55,009
BIRAC Fund( Non Recurring)	44,91,154	56,62,034
BIRAC Fund( Recurring)	2,10,84,981	10,50,17,220
	<b>25,76,16,416</b>	<b>36,76,00,597</b>
<b>Others Payable</b>		
Statutory Liabilities	6,03,979	17,35,256
Liability under DBT-BMGF-PMU	63,33,536	-
Others	70,49,502	79,14,126
	<b>1,39,87,017</b>	<b>96,49,382</b>
<b>TOTAL</b>	<b>27,16,03,433</b>	<b>37,72,49,979</b>

## 4. Short Term Provisions

Particulars	Figures as at the end of the current reporting period (31.03.2014)	Figures as at the end of the previous reporting period (31.03.2013)
Provision for Income Tax	-	2,78,465
<b>TOTAL</b>	<b>-</b>	<b>2,78,465</b>

**5 Schedule of Fixed Assets:**

(Amount in Rs.)

Particulars	Rate of Dep.	Balance as on 1.4.2013	GROSS BLOCK			DEPRECIATION				NET BLOCK	
			Additions	Sales/ Adjustments*	Total	upto 31.3.2013	For the Year	Adjustment	Total	WDV as on 31.3.2014	WDV as on 31.3.2013
Tangible											
Furniture & Fixtures	18.10%	34,56,952	26,85,011	(34,56,952)	26,85,011	1,14,856	1,93,337	(1,14,856)	1,93,337	24,91,674	33,42,096
Mobiles	13.91%	-	31,517	-	31,517	-	460	-	460	31,057	-
Computer	40%	2,74,300	17,92,029	-	20,66,329	10,520	5,63,098	-	5,73,618	14,92,711	2,63,780
Total Tangible		37,31,252	45,08,557	(34,56,952)	47,82,857	1,25,376	7,56,895	(1,14,856)	7,67,415	40,15,442	36,05,876
Intangible											
Softwares	40%	6,06,744.00	1,19,275	-	7,26,019	68,354	2,60,975	-	3,29,329	3,96,690	5,38,390
Total Intangible		6,06,744.00	1,19,275	-	7,26,019	68,354	2,60,975	-	3,29,329	3,96,690	5,38,390
<b>TOTAL</b>		<b>43,37,996.00</b>	<b>46,27,832</b>	<b>(34,56,952)</b>	<b>55,08,876</b>	<b>1,93,730</b>	<b>10,17,870</b>	<b>(1,14,856)</b>	<b>10,96,744</b>	<b>44,12,132</b>	<b>41,44,266</b>
Previous Years Figures		-	43,37,996	-	43,37,996	-	1,93,790	-	1,93,730	41,44,266	

\*Note: The adjustment of fixed assets is due to transfer of the assets from BIRAC to BMGF-DBT-PMU.

**6 Non - Current Assests**

(Amount in Rs.)

Long Term Loans & Advances	Figures as at the end of the current reporting period (31.03.2014)	Figures as at the end of the previous reporting period (31.03.2013)
Security Deposits	1,05,28,300	11,20,000
Security Deposits-Rent-BMGF	12,60,315	-
Loans - BIPP/ SIBRI through BCIL	-	7,00,000
Long Term Loans & Advances-Secured, considered good (Taken over from Biotech Consortium India Limited, Current portion of long term loans & advances disclosed in Notes to Accounts No. 15.4)	2,50,25,74,145	
Less: The current portion of the Long Term Loans & advances are disclosed under the head Current assets (Loans & Advances)*	51,46,64,024	1,98,79,10,121
Unsecured, considered good	NIL	NIL
Doubtful	NIL	NIL
<b>TOTAL</b>	<b>1,99,96,98,736</b>	<b>18,20,000</b>

\*The current portion of Long term Loans & Advances of Rs. 51,46,64,024.00 includes the overdues as per Note no. 15.4 of Notes to Accounts.

**7 Current Assets**

(Amount in Rs.)

Cash & Cash Equivalents	Figures as at the end of the current reporting period (31.03.2014)	Figures as at the end of the previous reporting period (31.03.2013)
Cash in Hand	18,771	14,030
Balances with Banks in Saving accounts		
Corporation Bank under BIRAC	76,09,734	13,08,03,279
Corporation Bank Flexi Account under BIRAC	15,647	-
SBH balance under I&M	11,01,23,742	3,75,40,690
Bank FDR under I&M (SBH)	1,93,85,503	-
Bank FDR under WT (SBH)	10,81,62,118	-
SBH balance under WT	10,62,938	10,32,97,534
SBH balance under BMGF	1,63,70,481	-
<b>TOTAL</b>	<b>26,27,48,934</b>	<b>27,16,55,533</b>

**8 Other Current Assets**

(Amount in Rs.)

Other Current Assets	Figures as at the end of the current reporting period (31.03.2014)	Figures as at the end of the previous reporting period (31.03.2013)
Current portion of Long Term Loans & Advances, Secured Considered Good**	51,46,64,024	-
Unsecured, considered good	Nil	Nil
Doubtful	Nil	Nil
Accrued Interest on FDRs	4,38,712	-
Recoverable from Government Agencies (Tax Credit)	8,15,523	-
Prepaid Expenses	1,92,50,625	28,80,578
Unspent amount with BCIL	1,22,24,864	11,14,90,000
Advances Recoverable in cash or in kind or for Value	2,11,28,341	7,42,180
<b>TOTAL</b>	<b>56,85,22,089</b>	<b>11,51,12,758</b>

\*\*The current portion of Long term Loans & Advances of Rs. 51,46,64,024.00 includes the overdues as per Note no. 15.4 of Notes to Accounts.

**9 Income**

(Amount in Rs.)

Grants Received & Utilized	Figures for the current reporting period (31.03.2014)	Figures for the previous reporting period (31.03.2013)
<b>Grants Utilised under Schemes:</b>		
Grants Utilised From I&M Towards BIPP (I)	11,94,57,575	15,14,000
Grants Utilised From I&M Towards BISS (I)	19,25,64,000	-
Grants Utilised From I&M Towards SIBRI(I)	6,70,58,258	-
Grants Under BIG (I)	5,50,66,671	-
Grants Under CRS (I)	1,20,55,000	-
Grants Under IP (I)	1,11,17,912	-
Grants Under TT (I)	1,63,40,776	-
Utilisation of BIRAC Funds	2,52,32,849	-
Grants against Manpower Expenses	2,20,69,034	53,44,991
Grants against Recurring Expenses	9,67,05,006	3,94,71,780
<b>TOTAL</b>	<b>61,76,67,081</b>	<b>4,63,30,771</b>

**10 Other Income**

(Amount in Rs.)

Particulars	Figures for the current reporting period (31.03.2014)	Figures for the previous reporting period (31.03.2013)
Interest Received - Bank Accounts	80,93,580	16,14,517
Management Fees From BMGF	5,73,217	-
Foreign Exchange Fluctuation	1,40,914	-
Misc. Income	26,087	700
<b>TOTAL</b>	<b>88,33,798</b>	<b>16,15,217</b>

**11 Programmatic Expenses\***

(Amount in Rs.)

Particulars		Figures for the current reporting period (31.03.2014)	Figures for the previous reporting period (31.03.2013)
<u>Industry &amp; Manufacturing (I &amp; M)</u>			
<b>Biotechnology Industry Partnership Programme (BIPP):</b>			
Grants Disbursed		9,06,74,900	-
Project Expenditure		2,87,82,676	-
<b>Small Business Innovation Research Initiative (SBIRI):</b>			
Grants Disbursed		4,42,23,361	-
Project Expenditure		2,28,34,897	-
<b>Bio Incubators Support Scheme (BISS):</b>			
Grants Disbursed		19,25,64,000	-
	<b>(A)</b>	<b>37,90,79,834</b>	-
<b>Grants under BIRAC</b>			
Contract Research Scheme		1,20,55,000	-
Biotech Ignition Grants		5,23,57,832	-
Intellectual Property		1,11,17,912	-
Technology Transfer & Acquisition		1,63,40,776	-
Regional Centers		50,38,110	-
	<b>(B)</b>	<b>9,69,09,630</b>	-
<b>Other Activity Expenditure</b>			
Entrepreneurship Development		29,83,697	-
IP Cell Activity		55,82,657	-
Sponsorship		61,12,151	1,00,492
Workshop Expenses		35,75,194	23,58,481
Discovery Research Accelerator		19,41,040	-
Management Fee (BIG)		27,08,839	-
	<b>(C)</b>	<b>2,29,03,578</b>	<b>24,58,973</b>
<b>Total (A+B+C)</b>		<b>49,88,93,042</b>	<b>24,58,973</b>

\*Previous year's figures have been regrouped and reclassified as and where necessary to make the figures comparable.

**11A Programme Management Unit DBT & BMGF**

(Amount in Rs.)

Particulars		Figures for the current reporting period (31.03.2014)	Figures for the previous reporting period (31.03.2013)
Project Expenditure	<b>(A)</b>	1,86,58,213	-
<u>Less:</u>			
Matching Project Funds from DBT		93,29,106	-
Matching Project Funds from BMGF		93,29,107	-
	<b>(B)</b>	1,86,58,213	-
	<b>(A-B)</b>	-	-

**12 Employees Benefit Expenses****(Amount in Rs.)**

Particulars	Figures for the current reporting period (31.03.2014)	Figures for the previous reporting period (31.03.2013)
Salary & Allowances to Staff	2,06,77,289	45,97,491
Employer's Contribution to Provident Fund	13,91,745	7,47,500
<b>TOTAL</b>	<b>2,20,69,034</b>	<b>53,44,991</b>

**13 Other Expenses\*****(Amount in Rs.)**

Particulars	Figures for the current reporting period (31.03.2014)	Figures for the previous reporting period (31.03.2013)
Travel	75,53,051	47,65,436
Meetings & Conferences	91,30,622	69,41,087
Advertisement	1,03,46,122	64,98,600
Building Maintenance	9,04,114	6,85,085
Legal & Professional	15,64,758	45,20,174
ROC Fees	30,950	-
Office Expenses	25,76,739	6,44,156
Power & Electricity	9,27,630	2,16,630
Printing & Stationery	10,87,990	4,15,830
Rent	4,59,91,700	97,95,181
Sitting Fees & TA and DA	14,12,985	3,92,735
Fees & Subscription	1,18,51,195	8,32,928
Conveyance Expenses	17,44,100	8,31,130
Expenses Incurred for BIPP Scheme	-	15,14,000
Preliminary Exp Written Off	-	2,76,875
Security Service	6,49,301	2,77,747
Postage & Telephone Expenses	7,22,464	1,29,282
Auditor's Payment		
Audit Fee 134832		
Out-of-pocket expense 5056	1,39,888	56,180
Bank Charges	21,454	2,305
Misc. Expenses	49,943	8,321
<b>TOTAL</b>	<b>9,67,05,006</b>	<b>3,88,03,682</b>

\*Previous year's figures have been regrouped and reclassified as and where necessary to make the figures comparable.



## 14. SIGNIFICANT ACCOUNTING POLICIES:

### 1. Corporate Information:

Biotechnology Industry Research Assistance Council (BIRAC) “the Company” is a Section 25 “Not-for-Profit Company” incorporated under the provisions of the Companies Act, 1956, vide Registration No. U73100DL2012NPL233152 dated 20th March 2012. BIRAC is also registered under Section 12A of the Income Tax Act 1961. The Company is engaged in nurturing, promoting and mentoring Research and Development in Biotech Sector.

### 2. Basis of Preparation of Financial Statements:

The Financial Statements of the Company are prepared in accordance with Generally Accepted Accounting Principles in India (Indian GAAP). These are in compliance, in all material respects, with the Accounting Standards notified under the Companies (Accounting Standards) Rules, 2006, (as amended) and the relevant provisions of the Companies Act, 1956 and Companies Act 2013. The Financial Statements are prepared on accrual basis and under the historical cost convention.

Preparation of Financial Statement requires the Management to make estimates and assumptions in regard to the reported amount of assets, liabilities, expenses and income of the reporting period. The estimates used in preparation of the Financial Statement are prudent and reasonable. The difference between the actual results and estimates, if any, are recognised in the reporting period in which the results are known and / or materialised.

#### 2.1 Revenue Recognition

##### i) Interest:

- a) Interest on loan granted is recognised on a time proportion basis taking into account the amount outstanding and applicable rate of interest. Additional interest on the delayed payment is recognised on receipt basis.
  - b) Interest against time deposits with banks are accounted on accrual basis.
- ii) Royalty is recognised on accrual basis on acknowledgement of amount due by the beneficiary.
  - iii) Management Fee is recognised on accrual basis in accordance with the terms of the relevant agreement.

#### 2.2 Grants-in-Aid:

Income by way of grants- in-aid has been recognised under Matching Principle of Accounting. All expenditure incurred out of the grants-in-aid, comprising of grants disbursed and other programmatic expenditure are matched with equal amount of income and adjusted against the grants- in -aid. Unspent balances of Grants- in -aid are carried forward as liability to be utilised in subsequent years.

The application of funds for disbursement of loans under different schemes are shown as Loans and Advances under Non-Current Assets.

#### 2.3 Expenditure:

All expenses are accounted for on accrual basis.

Funds released as grants-in-aid are treated as expenditure in the Income & Expenditure Account. Further, amount unutilised as per the Utilisation Certificates received on completion of the projects are accounted as Income.

#### 2.4 Fixed Assets:

Fixed Assets are stated at cost, net of accumulated depreciation and accumulated impairment losses, if any.

Gains or losses arising from de-recognition of fixed assets are measured as the difference between the net disposal proceeds and the carrying amount of the assets derecognized.

The carrying amounts of assets are reviewed at each Balance Sheet date.

## **2.5 Depreciation and Amortisation:**

Depreciation on assets is provided on written down value (WDV) method prescribed under Schedule XIV to the Companies Act, 1956.

Depreciation on fixed assets added/disposed off during the year/period is provided on pro-rata basis with reference to the date of addition/disposal. Individual Assets costing up to Rs. 5,000 are treated as expenditure, in full, in the year of purchase.

## **2.6 Intangible Assets :**

Intangible assets acquired are measured separately at cost. Intangible assets are carried at cost less accumulated amortization and accumulated impairment losses, if any. Internally, generated intangible assets are not capitalized and expensed off in the Statement of Income and Expenditure in the year in which the expenditure is incurred.

Intangible assets are amortized on a written down value (WDV) method at rates prescribed under Schedule XIV to the Companies Act, 1956.

## **2.7 Foreign Exchange Transactions/Translation:**

Foreign currency transactions and balances: Foreign Currency Transfer is made as per the approved Government guidelines. For any contribution being received from foreign entities, the necessary approval is obtained under the Foreign Contribution (Regulation) Act, 2010.

- (i) **Initial Recognition:** Foreign currency transactions are recorded in the reporting currency by applying the exchange rate between the reporting currency and the foreign currency at the date of the transaction.
- (ii) **Conversion:** Foreign Currency monetary items are retranslated using the exchange rate prevailing at the reporting date.
- (iii) **Exchange Difference:** Exchange differences arising on long-term foreign currency monetary items related to acquisition of a fixed asset are capitalized and depreciated over the remaining useful life of the asset. The exchange differences on other foreign currency monetary items are accumulated in 'Foreign Currency Monetary Item Translation Difference Account' and amortized over the remaining life of the concerned monetary item.

All other exchange differences are recognized as income or as expenses in the period in which they arise.

## **2.7 Employees Benefits:**

- a) All the employees of the Company are on contractual basis. Provision of Employer's contribution is made as per the provisions of Employees Provident Fund Act, 1952.
- b) Gratuity to employees shall be accounted as and when it becomes due.

## **2.8. Provisions & Contingent Liabilities:**

- a) Funds sanctioned and yet to be released till the reporting period due to timing difference of milestone are not taken as liability, these are accounted as expenses on actual release of payment.
- b) A provision is recognized when the company has present obligations as a result of past event. It is probable that an outflow of resources embodying economic benefits will be required to settle the obligations and reliable estimate can be made of amount of the obligation. Provisions are not discounted at their present value and are determined based on the best estimate required to settle the obligation at the reporting date. These estimates are reviewed at each reporting date and adjusted to reflect the current best estimates.

## 2.9. Earning Per Share:

The Company is a Section 25 “Not-for-Profit Company”. It does not generate any income/revenue from its activities. It does not distribute any dividend to its shareholders. However, for the compliance of AS – 20 the Company has computed EPS as under.

- a) Basic earnings per share are calculated by dividing the net income or loss for the period attributable to equity shareholders by the weighted average number of equity shares outstanding during the period.
- b) For the purpose of calculating diluted earnings per share, the net profit or loss for the period attributable to equity shareholders and the weighted average number of shares outstanding during the period are adjusted for the effects of all diluting potential equity shares.

For **SAMPRK & ASSOCIATES**  
(Chartered Accountants)

Sd/-  
**CA. Pankaj Sharma**  
(Partner)  
Membership No. 093446

Sd/-  
**Kavita Anandani**  
(Company Secretary)

Sd/-  
**Renu Swarup**  
(Managing Director)  
DIN No.01264943

Sd/-  
**K.VijayRaghavan**  
(Chairman)  
DIN No.02721859

## 15. Notes to Accounts for the year ended March 31, 2014

- 15.1** Biotechnology Industry Research Assistance Council receives funds from Department of Biotechnology (DBT), Ministry of Science & Technology, Govt of India by way of grant-in-aid for its operation. During the FY 2013-14, Grant-in-aid amounting to Rs 15 crore and Rs 62.86 crore respectively under BIRAC funds and I & M Sector funds were received.
- 15.2** During the current financial year BIRAC disbursed Rs.6.44 crore and Rs.63.24 crore respectively under BIRAC Funds and I & M Sector funds on the schemes as per details as under:

(Amount in Rs.)

BIRAC FUNDS	Grant	Loan	Total Amount
Contract Research Scheme(CRS)	1,20,55,000	0	1,20,55,000
Biotech Ignition grant Scheme (BIG)	5,23,57,832	0	5,23,57,832
<b>TOTAL</b>	<b>6,44,12,832</b>	<b>0</b>	<b>6,44,12,832</b>
I&M SECTOR FUNDS	Grant	Loan	Total Amount
Bio-Incubators Support Scheme(BISS)	19,25,64,000	0	19,25,64,000
Biotechnology Industry Partnership programme(BIPP)	9,06,74,900	24,44,69,500	33,51,44,400
Small Business Innovation Research Initiative(SBIRI)	4,42,23,361	6,04,82,000	10,47,05,361
<b>Total</b>	<b>32,74,62,261</b>	<b>30,49,51,500</b>	<b>63,24,13,761</b>
<b>GRAND TOTAL</b>	<b>39,18,75,093</b>	<b>30,49,51,500</b>	<b>69,68,26,593</b>

- 15.3** BIRAC also disbursed Rs.1.63 crore and Rs.1.11 crore on facilitating Technology transfer and Intellectual property respectively. The disbursements were made in tranches as per the milestones determined for the projects.
- 15.4** As on 31.3.2014, a Loan Portfolio (consisting of 210 accounts) held by Biotech Consortium India Limited (BCIL) for the schemes designated as BIPP & SBIRI under I&M Sector has been taken over as per the directions of the Department of Biotechnology, Government of India. The details are given as under:

Sl.No	Particulars as at 31.3.2014	Amount in Rs.
1	Principal Amount outstanding	2,37,10,83,763
2	Accrued interest outstanding	13,14,90,382
3	Accrued Additional interest on delayed payment	3,43,58,461
4	Recovery amount remitted to BIRAC by BCIL	2,23,54,203
5	Overdue amount	20,22,48,977
6	Delinquent loan outstanding	72,35,59,400

The current maturities of the long term loan & advances, secured, considered good, amounting to Rs.51,46,64,024/- unsecured considered good Nil, Doubtful Nil are disclosed under "Other Current assets"(refer to Schedule 6 and 8).

### Age wise overdue position:

Overdue Position	Overdue Amount	Loan outstanding
	Amount (Rs.)	Amount (Rs.)
Overdue upto one year	3,33,77,415	21,29,32,000
Overdue more than one year	16,88,77,562	51,06,27,400
<b>Total Overdue</b>	<b>20,22,54,977</b>	<b>72,35,59,400</b>

Out of the delinquent loans outstanding of Rs.72.36 crore, Rs.51.06 crore pertains to the category where necessary remedial action are to be taken.

## 15.5 Recovery

Amount recovered as repayment of loan and Interest / royalty income earned on the portfolio up to 31.3.2014 amounting to Rs.3.38 crore is shown as portfolio reserve realised under Reserves & Surplus and not considered as BIRAC's income as the portfolio is taken over as at 31.3.2014.

## 15.6 Suit Filed Accounts:

15.6.1 Suits filed by the company: Nil

15.6.2 Suits filed against the company: Nil

## 15.7 Programme Management Unit – DBT and BMGF

Department of Biotechnology (DBT) and Bill Melinda Gates Foundation (BMGF) have signed a MOU for supporting priority areas of research. BIRAC has been entrusted the responsibility to be the "Technical Management Unit". In this regard, BIRAC established a Programme Management Unit to administer programmes, of affordable product development in the area of Health Care and Agriculture. During the current year BIRAC received funds amounting to Rs.2.97 crore from BMGF for setting up of programme management unit. Expenditure amounting to Rs.1.86 crore incurred during the year which is adjusted in equal proportion amongst DBT and BMGF. Interest earned on the same is not considered as income BIRAC.

## 15.8 DBT- Wellcome Trust Programme

The amount received from Department of Biotechnology under DBT – Wellcome Trust Programme amounting to Rs.10.25 crore during the previous financial year along with interest amount is kept in a separate bank account. Board has approved a joint call on "Translational Medicines". MOU has been signed with Wellcome Trust. Permission from DBT is awaited for utilising the amount.

## 15.9 Prior Period adjustment:

A sum of Rs. 31,87,314/- was incurred for DBT-BMGF-PMU but was debited in the expenses of BIRAC. It has been rectified during the current financial year by crediting to prior period items as per Accounting Standard 5.

## 15.10 Related party disclosure:

The provisions of Accounting Standard-18 are not applicable as there is no transaction between a reporting enterprise and its related parties.

## 15.11 Provision for Tax:

No Provision for Income Tax has been made in the current year as registration under Section 12A of the India Income Tax 1961 has been received.

## 15.12 Foreign Exchange Transactions:

During the Current financial year the following income/expenditure has been incurred.

A. Income: NIL

B. Expenditure:

(i) Foreign Travel

(a) Directors: NIL

(b) Other Employees: US\$2300

(ii) Books, Journal and Database Subscription: US\$73688 & GBP 7548

(iii) Entrepreneurship Development: GBP 16918

CIF Value of import is NIL for the current financial year.



**BIOTECHNOLOGY INDUSTRY RESEARCH ASSISTANCE COUNCIL  
SUPPLEMENTARY SCHEDULES TO BALANCE SHEET**

**15.13 Supplementary Schedule on Scheme Balances**

**AS ON 31.03.2014**

<b>BIRAC FUNDS (I &amp; M ) SECTOR AMOUNT (RS)</b>				
<b>Opening balance of unutilised funds brought forward</b>				14,89,68,800
Add:	Funds received from DBT		62,85,56,000	
	Interest Earned From Bank - BCIL		1,80,16,062	64,65,72,062
				79,55,40,862
Less:	Amount given in different schemes			
	BIRAC	BISS	19,25,64,000	
	BCIL	BIPP/ SBIRI - Loans	30,49,51,500	
		BIPP/ SBIRI - Grants	13,48,98,261	63,24,13,761
				16,31,27,101
Less:	Loan through BCIL in previous year held as			
	Loan Recoverable, reversed since taken up as part of portfolio			7,00,000
				16,24,27,101
Less:	Exp incurred by BCIL (BIPP/SBIRI)			
	Management Fee		98,84,305	
	Project Fee		4,17,33,267	5,16,17,572
	<b>Balance carried forward</b>			<b>11,08,09,529</b>
<b>BIRAC FUNDS</b>				
	<b>Opening Balance</b>			10,50,17,220
Add:	Opening Balance of Manpower Fund		46,55,009	
	Opening Balance of Non Recurring Fund		56,62,034	1,03,17,043
				<b>11,53,34,263</b>
Add:	Recovered from BMGF-PMU (Prior period)			34,56,952
	Received from DBT			15,00,00,000
				26,87,91,215

Less:	Amount given in different ) schemes (Grants)			
	Contract Research Scheme		1,20,55,000	
	Biotech Ignition Grants		5,23,57,832	
	Biotech Ignition Grants - Management Fee		27,08,839	
	Intellectual Property		1,11,17,912	
	Regional Centers		50,38,110	
	Other activities		2,01,94,739	
	Technology Transfer & Acquisition		1,63,40,776	11,98,13,208
				<b>14,89,78,007</b>
Less:	Utilisation towards:			
	Manpower Expenses		2,20,69,034	
	Fixed Assets		46,27,832	
	Recurring Expenses		9,67,05,006	12,34,01,872
	<b>Balance carried forward</b>			<b>2,55,76,135</b>
<b>BMGF PMU</b>				
	Opening Balance			-
Add:	Received From BMGF		2,97,17,388	
	Received From DBT		-	2,97,17,388
Add::	Bank Interes			2,38,085
				2,99,55,473
Less: Expenditure				
	Manpower Expense		3,75,933	
	Meeting Expenses		15,91,835	
	Expenses for Space		1,20,72,271	
	Administraive Expenses		40,44,957	
	Management Fee		5,73,217	1,86,58,213
	<b>Unutilised Balance Carried Forward</b>			<b>1,12,97,260</b>
	Balance Fund			
	BMGF			2,05,07,324
	DBT (Recoverable)			(92,10,064)
				1,12,97,260
<b>WELLCOME TRUST</b>				
	Opening Balance			10,32,97,534
Add:	Bank Interest		30,65,404	
	FDR interest		31,80,133	
	Accrued Interest		3,90,421	66,35,958
	<b>Unutilised Balance Carried Forward</b>			<b>10,99,33,492</b>

## 15.14 Utilisation of Funds Paid to BCIL

<b>Opening Balance</b>				<b>11,14,90,000.00</b>
Add:	Amount received from BIRAC under I & sector		37,00,00,000.00	
	Diff of opening balance		221.00	
	Bank Interest Earned		1,80,16,062.00	38,80,16,283.00
				49,95,06,283.00
Less;	Grants given under schemes		13,48,98,261.00	
	Management Fee		56,98,391.00	14,05,96,652.00
Less: Loan given under schemes				30,49,51,500.00
Less Expenditure incurred				4,17,33,267.00
Closing balance as per BCIL UC				1,22,24,864.00

\*Amount of Rs.1,14,66,000/- is also to be received from BCIL with respect to the amount recovered from Borrowers.

**15.15** The amendments made in the significant accounting policies for the year 2013-14 are explanatory in nature and clarificatory. There is no financial impact on the amendments made to significant accounting policies for the year 2013-14.

**15.16** Previous year's figures have been regrouped and reclassified as and where necessary to make the figures comparable.

For **SAMPRK & ASSOCIATES**  
(Chartered Accountants)

Sd/-  
**CA. Pankaj Sharma**  
(Partner)  
Membership No. 093446

Sd/-  
**Kavita Anandani**  
(Company Secretary)

Sd/-  
**Renu Swarup**  
(Managing Director)  
DIN No.01264943

Sd/-  
**K.VijayRaghavan**  
(Chairman)  
DIN No.02721859

**COMMENTS OF THE COMPTROLLER AND AUDITOR GENERAL OF INDIA UNDER SECTION 619 (4) OF THE COMPANIES ACT, 1956 ON THE ACCOUNTS OF BIOTECHNOLOGY INDUSTRY RESEARCH ASSISTANCE COUNCIL FOR THE YEAR ENDED 31st MARCH 2014.**

The preparation of financial statements of **Biotechnology Industry Research Assistance Council** for the year ended 31 March 2014 in accordance with the financial reporting framework prescribed under the Companies Act, 1956 is the responsibility of the management of the company. The Statutory Auditors appointed by the Comptroller and Auditor General of India under Section 619 (2) of the Companies Act, 1956 are responsible for expressing opinion on these financial statements under Section 227 of the Companies Act, 1956 based on the independent audit in accordance with the Standards on Auditing prescribed by their professional body, the Institute of Chartered Accountants of India. This is stated to have been done by them vide their revised Audit Report dated **12.08.2014**.

I, on the behalf of the Comptroller and Auditor General of India, have conducted a supplementary audit under Section 619 (3) (b) of the Companies Act, 1956 of the financial statements of **Biotechnology Industry Research Assistance Council** for the year ended 31 March 2014. This supplementary audit has been carried out independently without access to the working papers of the statutory auditors and is limited primarily to inquiries of the statutory auditors and company personnel and a selective examination of some of the accounting records. In view of the revisions made in the financial statements by the management, as a result of my audit observations highlighted during supplementary audit as indicated in the Para No. 1 of revised Auditor's Report, I have no further comments to offer upon or supplement to Statutory Auditor's report under Section 619(4) of the Companies Act, 1956.

For and on the behalf of the Comptroller  
and Auditor General of India

Sd/-

**(Atreyee Das)**

Director General of Commercial Audit &  
Ex-Officio Member, Audit Board-IV

Place: New Delhi.

Date: 03.09.14

## NOTES



## NOTES



### Attendance Slip

Name of the Member/proxy (In Block Letters)	
Address of Member /Proxy:	
Folio No. :	
No of Shares Held	

I certify that I am a member /proxy for the member of the Company.

I hereby record my presence at the 2<sup>nd</sup> Annual General Meeting of the Company held on Tuesday ,30<sup>th</sup> September 2014 at 10:00 a.m. at MTNL Building, 1st Floor, 9 CGO Complex, Lodhi Road, New Delhi-110003

.....  
Member's /Proxy's Signature

### PROXY FORM

[Pursuant to Section 105(6) of the Companies Act, 2013 and Rule 19 (3) of the Companies (Management and Administration) Rules, 2014]

Name of the Member(s)	E-mail ID:	
Registered Address	Folio No. :	

I/We, being the member(s) of ..... shares of the above named Company, hereby appoint:

- (1) Name:.....  
Address: .....  
E-mail Id: .....  
Signature: ..... or failing him/her;
- (2) Name:.....  
Address: .....  
E-mail Id: .....  
Signature: .....,

as my/our proxy to attend and vote (on a poll) for me/us and on my/our behalf at the 2<sup>nd</sup> Annual General Meeting of the Company, to be held on 30<sup>th</sup> September 2014 at 10:00 a.m. at MTNL Building, 1<sup>st</sup> Floor , 9 CGO Complex, Lodhi Road ,New Delhi-110003. New Delhi-110 003 and at any adjournment thereof in respect of such resolutions as are indicated below:

S.No	Resolutions	For	Against
1.	Ordinary Business To receive, consider and adopt the Audited Financial Statement of the company as on March 31, 2014 together with the Reports of the Directors and Auditors, thereon and comments of the Comptroller & Auditor General of India in terms of Section 143 (6) & (7) of the Companies Act 2013		
2.	To authorise the Board of Directors of the Company to fix the remuneration of the Statutory Auditor for the Financial year 2014-15 in terms of provisions of Section 139(5) read with Section 142 of the Companies Act 2013 and to pass with or without modification(s) the following resolution as an Ordinary Resolution:		

Signed this ..... day of ..... 2014. Signature of the Shareholder \_\_\_\_\_

Signature of first proxy holder \_\_\_\_\_ Signature of Second proxy holder \_\_\_\_\_

\* Applicable for investors holding shares in electronic form.



**Notes:**

1. MEMBERS ENTITLED TO ATTEND AND VOTE MAY APPOINT ONE OR MORE PROXIES TO ATTEND AND VOTE INSTEAD OF THEMSELVES. PROXIES TO BE VALID MUST BE RECEIVED AT THE REGISTERED OFFICE OF THE COMPANY NOT LESS THAN FORTY-EIGHT HOURS BEFORE THE APPOINTED TIME OF THE MEETING
2. Only bonafide members of the Company whose names appear in the Register of Members in possession of valid attendance slips duly filed and signed will be permitted to attend the meeting. The company reserves its right to take all steps as may be deemed necessary to restrict non-members from attending the meeting.
3. All documents referred in the notice are open for inspection at the Registered Office of the Company between 10.00 a.m. to 1.00 p.m. on any working day up to the date of Annual General Meeting and also at the meeting.
4. It will be appreciated that queries, if any, on accounts and operations of the Company are sent to the Regd. Office of the company ten days in advance of the meeting so that the information may be made readily available.
5. Members are requested to notify change of address, if any, to the company.





**Biotechnology Industry Research Assistance Council**  
(A Govt. of India Enterprise)